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ABSTRACT 
 
The Epstein–Barr Virus (EBV) is a human gamma herpes virus that infects 
more than 90% of the human population worldwide.  It is commonly known in the 
US as the cause of Infectious Mononucleosis, and around the world as the cause 
of nasopharyngeal carcinoma and malignant lymphomas such as non-Hodgkin 
lymphoma, endemic Burkett’s lymphoma and Hodgkin lymphoma.  Additionally, 
the EBV is used to immortalize cells to create cell lines for in-vitro studies.  
To what extent the EBV changes the cell machinery through gene 
regulation is poorly understood to date.  There has been no study that examined 
the whole transcriptome perturbations between primary lymphocytes (non-
Immortalized) compared to the EBV immortalized lymphoblastoid cells.  To 
address this oversight, this study re-examined the whole transcriptome from two 
independent studies on different Affymetrix platforms.   
Our analyses identified 4,366 probe-sets corresponding to 1,598 genes 
that are have significantly different expression patterns between immortalized 
and primary B-cells.  We further show significant enrichment of these genes into 
168 different pathways.  Analysis of these expression profiles and pathway 
enrichment helps to give insight into the mechanisms used by the EBV to 
maintain immortalization of infected B cells. 
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INTRODUCTION 
General Introduction 
The Epstein-Barr virus (EBV) is a ubiquitous human gamma herpesvirus 
that infects about 90% of the population worldwide.  It infects mainly B cells and 
can remain latent for years.  Although usually a benign infection, the EBV can 
cause several diseases including Infectious Mononucleosis, Burkett’s lymphoma, 
Nasopharyngeal carcinoma, non-Hodgkin lymphoma and Hodgkin lymphoma 
(Kuppers, 2003).   
The EBV is also important due to its ability to immortalize cells to create 
cell lines for in-vitro studies.  Such cell lines have been used since the 1970s for 
countless experiments (Ali, 2009; Takacs, 2009).  Despite their common use, the 
way and extent to which the EBV changes the infected and immortalized B cell is 
still not fully described.  It is not known how the EBV alters the cellular machinery 
and expression levels in B cells.   
In order to aid in the characterization of these changes by the EBV, this 
study utilized a bioinformatic approach to examine and compare the whole 
transcriptome between primary and EBV-immortalized B cells.  Our analyses 
identified patterns of gene expression that were significantly different between 
immortalized and primary B-cells.  We further show significant enrichment of 
these differentially expressed genes into different biological pathways.   
The goal of this thesis research was to better understand how the EBV 
alters the expression levels in infected B cells.  The following sections provide 
background on the field of bioinformatics, microarray studies, and the EBV. 
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Bioinformatics 
 Bioinformatics is the field of science in which biology, computer science, 
and information technology merge into a single discipline.  The National Institutes 
of Health (NIH) defines Bioinformatics as approaches for expanding the use of 
biological, medical, behavioral or health data, including those to acquire, store, 
organize, archive, analyze, or visualize such data.  This is distinct from 
Computational Biology, which is defined as the development and application of 
data-analytical and theoretical methods, mathematical modeling and 
computational simulation techniques to the study of biological, behavioral, and 
social systems (NIH, 2000). 
In bioinformatic research, computers are used to gather, store, analyze 
and integrate biological and genetic information, which can then be applied to 
gene-based drug discovery and development.  The science of bioinformatics is 
essential to the use of genomic information in understanding human diseases 
and in the identification of new molecular targets for drug discovery.  The ultimate 
goal of the field is to enable the discovery of new biological insights and to create 
a global perspective from which unifying principles in biology can be discerned 
(NCBI, 2004). 
The need for bioinformatic capabilities has in large part been precipitated 
by the emerging fields of genomics, proteomics, and transcriptomics.  
Genomics 
 Genomics, a discipline in genetics concerning the study of the genomes 
of organisms, has had a particular influence on the growth of the bioinformatics 
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field due to the explosion of publicly available genomic information resulting from 
the Human Genome Project (Goulart, 2010).  Completed in 2003, the Human 
Genome Project (HGP) was a 13-year project coordinated by the U.S. 
Department of Energy and the NIH.  Project goals were to identify all the 
approximately 20,000-25,000 genes in human DNA, determine the sequences of 
the 3 billion chemical base pairs that make up human DNA, store this information 
in databases, improve tools for data analysis, transfer related technologies to the 
private sector, and address the ethical, legal, and social issues that may arise 
from the project (Goulart, 2010).  Though the HGP is finished, analyses of the 
data will continue for many years, requiring significant bioinformatic resources.  
Proteomics 
The tools of bioinformatics were also necessary for the advent of 
proteomics.  The goal of proteomics is a comprehensive, quantitative description 
of protein expression and its changes under the influence of biological 
perturbations such as disease or drug treatment.  Quantitative analysis of protein 
expression data has been obtained by high-throughput methods.  Such 
investigations lay the groundwork for construction of comprehensive databases 
of mechanisms (cataloguing possible biological outcomes), the next step after 
the completed cataloguing of genes and gene products.  Mechanism databases 
provide a roadmap towards effective therapeutic intervention that is more direct 
than that offered by conventional genomics approaches. (Anderson, 1998) 
Transcriptomics 
Gene expression describes the transcription of the information contained 
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within the DNA into messenger RNA (mRNA) molecules that then can be 
translated into the proteins needed to maintain cellular functions.  
Transcriptomics, also referred to as expression profiling, is the branch of 
molecular biology that deals with studying the expression levels of mRNA 
molecules produced in an individual or population of a particular cell type, often 
using high-throughput techniques based on DNA microarray technology (Chuan, 
2010).  
Expression profiling is an important next step after sequencing a genome.  
The genome has the complete set of instructions for making mRNA, but this 
transcription of DNA into mRNA is not constitutively active.  At any moment each 
cell makes mRNA from only a portion of the genes it carries, as the cell does not 
need constant translation of the mRNA into their respective proteins.  While the 
sequence gives information on the range of possible functions of the cell, the 
expression profile gives a picture of what the actual activity is at a given point in 
time (Chuan, 2010; Costa, 2010).  
There are many factors determining whether a gene is actively 
transcribing or not, and which mRNAs are actually being produced.  These 
factors can include such variables as the time of day, whether or not the cell is 
actively dividing, environmental stresses, and chemical signals from other cells.  
There are also certain cell types that express different genes, such as skin cells, 
liver cells and nerve cells (Chuan, 2010; Costa, 2010).  Therefore, an expression 
profile can allow one to deduce a cell's type, state, environment, reaction to a 
particular treatment and so forth.  Many such experiments can measure an entire 
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genome simultaneously. 
 
Expression Microarrays 
Overview 
A microarray is a tool for analyzing gene expression that consists of a 
small membrane or glass slide containing samples of many genes arranged in a 
regular pattern. The key physicochemical process involved in microarrays is DNA 
hybridization. Two DNA strands can hybridize if they follow the Watson-Crick 
rules of base pairing, the property of complementary nucleic acid sequences to 
specifically pair with each other by forming hydrogen bonds between 
corresponding nucleotide base pairs. (Tarca, 2006).  Southern and Northern 
blots also exploit this ability of a given mRNA molecule to bind specifically to, or 
hybridize to, the DNA template from which it originated.  A DNA array can be 
considered as a large-scale parallel Southern or Northern blot analysis as, 
instead of a gel, the probes are attached to the inert microarray surface (Tarca, 
2006; Alba, 2004). 
In order to create an expression array, mRNA must be extracted and 
purified from the tissues or cells under examination.  It must then be reverse-
transcribed into its DNA complement (complementary DNA, or cDNA) using 
reverse transcription polymerase chain reaction, or RT-PCR. RT-PCR includes 
three major steps (Tarca, 2006; Sabatier, 2010). The first step is reverse 
transcription (RT), in which RNA is reverse transcribed to cDNA using the 
enzyme reverse transcriptase. This step is crucial to be able to then perform 
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PCR, since DNA polymerase can act only on DNA templates. The next step 
involves the denaturation of the RNA-cDNA hybrid. The final step of PCR 
amplification is DNA extension from the bound primers using the thermostable 
Taq DNA polymerase (Tarca, 2006; Sabatier, 2010).  
After the cDNA is amplified it is then labeled with a dye (typically 
fluorescent), and hybridized onto the array surface, which is a glass slide or 
membrane.  In general, the term ‘‘probe’’ is used to describe the nucleotide 
sequence that is attached to the microarray surface whereas the word ‘‘target’’ in 
microarray experiments refers to what is hybridized to the probes (Tarca, 2006; 
Sabatier, 2010; Alba, 2004).  The hybridization techniques used depend upon 
which type of array is needed.  Microarrays can be broadly classified according 
to at least three criteria: 1) length of the probes; 2) manufacturing method; and 3) 
number of samples that can be simultaneously profiled on one array.   
 When classifying by the length of the probes, there are two types of arrays:  
‘‘cDNA arrays,’’ which use probes up to thousands of base pairs (bps) long, and 
‘‘oligonucleotide arrays,’’ which use shorter probes (50 bps or less).  Arrays 
based upon manufacturing methods include: ‘‘deposition’’ of previously 
synthesized sequences and ‘‘in-situ synthesis.’’  Usually, cDNA arrays are 
manufactured using deposition, while oligonucleotide arrays are manufactured 
using in-situ technologies (Tarca, 2006; Alba, 2004).  In-situ technologies 
include: ‘‘photolithography’’ (eg, Affymetrix), ‘‘ink-jet printing’’ (eg, Agilent), and 
‘‘electrochemical synthesis’’ (eg, Combimatrix).  The third criterion for the 
classification of microarrays refers to the number of samples that can be profiled 
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on one array. ‘‘Single-channel arrays’’ analyze a single sample at a time, 
whereas ‘‘multiple-channel arrays’’ can analyze two or more samples 
simultaneously.  An example of an oligonucleotide, single-channel array is the 
Affymetrix GeneChip (Sabatier, 2010). 
After thorough washing of the completed array, as described above 
labeled cDNA hybridized to the slide or membrane.  In some cases, hybridization 
is done simultaneously with reference cDNA to facilitate comparison of data 
across multiple experiments. The labeled cDNAs that represent mRNAs in the 
cell will then hybridize to their synthetic complementary DNAs attached on the 
microarray slide. Affymetrix arrays have about twenty probes for the same cDNA 
target.  Half of these are "mismatch spots", which do not precisely match the 
target sequence (Tarca, 2006).  These can theoretically measure the amount of 
nonspecific binding for a given target.  
The next step is to generate an image using laser scanning (or 
autoradiographic imaging if the cDNA is radioactively labeled) in order to 
measure the fluorescent intensity for each spot/areas on the microarray slide. 
The principle behind the quantification of expression levels is that the amount of 
fluorescence measured at each sequence-specific location is directly proportional 
to the amount of mRNA with complementary sequence present in the sample 
analyzed (Tarca, 2006).  These experiments do not provide data on the absolute 
level of expression of a particular gene (true concentrations of mRNA), but are 
useful to compare the expression level among conditions and genes, such as 
health versus a particular disease.  Thus, if a gene is over expressed in a certain 
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disease state, then more sample cDNA, as compared to the control cDNA, will 
hybridize to the spot representing that expressed gene (Alba, 2004; Sabatier, 
2010).  In turn, the spot will fluoresce the specified color with greater intensity 
than the other.  
 At this point, the resulting images are used to generate a dataset.  This 
dataset requires a certain amount of ‘‘preprocessing’’ prior to the analysis and 
interpretation of the results.  This step extracts or enhances meaningful data 
characteristics and prepares the dataset for the application of data analysis 
methods (Suárez, 2009).  An example of preprocessing is taking the logarithm of 
the raw intensity values. 
 Normalization is a particular type of preprocessing performed in order to 
account for systematic differences across datasets.  Dye bias is a perfect 
example of the need for normalization.  This imbalance can occur in a two-color 
cDNA array when, for example, the raw intensities of the sample labeled with the 
green dye (Cy3) may appear consistently higher than those of the sample 
labeled with the red dye (Cy5).  Thus, simply considering the ratios between the 
green and red intensities would not accurately reflect the ratios between the 
amounts of mRNA in the sample (Suárez, 2009; Tarca, 2006).   
Affymetrix arrays specifically are subject to another type of problem, 
termed “array bias.”  Here, the intensities of the probes on a given array can be 
consistently higher or lower than those on other arrays (Suárez, 2009).  
Therefore, comparing the intensities of the same probe(s) on the different arrays 
can introduce serious errors if a normalization step is not performed first.  
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Raw Affymetrix data incorporate miss-match spots.  Robust Multichip 
Average (RMA) is a normalization approach that does not take advantage of 
these mismatch spots, but still must summarize the perfect matches through 
median polish (Tarca, 2006).  Quantile normalization, also part of RMA, is one 
sensible approach to normalize a batch of arrays in order to make further 
comparisons meaningful (Suárez, 2009).   
Also popular is the Affymetrix MAS5 normalization algorithm, which takes 
a set of Perfect Match (PM) and Mis-Match (MM) probes, and uses these to 
generate a single value representing the estimated amount of transcript in 
solution, as measured by that probeset (Grant, 2007). 
To do this, .DAT files with array images are processed to make a .CEL 
file, which contains measured intensities for each probe on the array.  These 
.CEL files are analyzed by the expression algorithm. 
Not only do Affymetrix arrays contain PM and MM spots designed to 
measure transcript levels, they also contain a series of control spots that, for 
example, delineate the edge of the array and help the image analysis software 
align the array properly (Grant, 2007). These spots are not considered by the 
analysis algorithm and are simply ignored. 
Applications of Microarray Analyses 
 There are several different types of applications of microarrays in medicine, 
in other words, different type of studies that one can perform.  The first is a class 
comparison study, which involves finding differences in expression levels 
between predefined groups of samples (Grant, 2007).  An example would be the 
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identification of genes differentially expressed in the epithelial cells of healthy 
people compared to those with malignant melanoma.    
 A class prediction study compares a sample to known gene expression 
profiles, such as in order to predict whether or not a patient is at risk for 
developing a certain disease.  This requires the construction of a classifier (a 
mathematical model) able to analyze the gene expression profile of a sample and 
predict how it matches with known profiles (Grant, 2007).  Once expression 
patterns of various genes involved in different diseases have been characterized, 
cDNA derived from diseased tissue from any individual can be hybridized to 
determine whether that individual’s expression pattern matches that of a known 
disease (Grant, 2007; Suárez, 2009; Tarca, 2006).  
 Another type of application involves analyzing a given set of gene 
expression profiles with the goal of discovering subgroups that share common 
features, known as class discovery (Grant, 2007; Suárez, 2009).  This type of 
study is conducted in order to generate a molecular taxonomy of a certain 
disease.  For example, the study would measure the expression profiles of a 
large number of people who suffer from malignant melanoma in order to identify 
subgroups of patients who have a similar gene expression profile.  In other 
words, the study would identify how many molecular types of malignant 
melanoma are in that sample (Tarca, 2006). 
 
Limitations and Problems of Microarray Studies  
 Despite recent advances in microarray technology and the rapid 
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development of bioinformatic tools, it is important to note that data obtained from 
cDNA microarrays have their limitations.  While cDNA microarrays and 
expression profiling can be very informative, the data obtained using these 
techniques should continue to be analyzed with caution, as expression artifacts 
are not uncommon.  
Artifacts 
 One important note is that different expressed sequence tag (EST) clones 
that originate from the same gene (i.e. pseudo-replicates) do not always result in 
the same expression profiles, even though they are on the same array (Giorgi, 
2010).  Expression artifacts could stem from a number of different issues, such 
as non-specific hybridization, annotation errors (i.e. a clone is not the expected 
sequence), chimeric clones, disparities in length of EST inserts, array elements 
that have multiple EST sequences (i.e. clone contamination) and secondary 
structures that can occur in nucleic acids (Nadon, 2002).  
 Although certainly an issue, expression profiling artifacts do not 
completely prevent the use of cDNA microarrays to gain biologically relevant 
expression data.  Nevertheless, until artifacts can be completely eliminated, 
microarray data should be interpreted with appropriate caution and evidence 
should be verified whenever possible. (Alba, 2004; Giorgi, 2010) 
Accuracy  
When microarray experiments are conducted within their optimal range, 
measurements reflect the magnitude and direction of expression changes of 
approximately 70-90% of genes (Alba, 2004; Giorgi, 2010).  The magnitude of 
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expression changes observed in microarray experiments is often different from 
those measured with other technologies, such as real-time quantitative reverse 
transcriptase polymerase chain reaction (qRT- PCR).  In general, microarray 
data exhibit a compression of the fold changes when compared to the fold 
change derived from qRT-PCR (Nadon, 2002). 
 Hybridization replicates increase the accuracy of measurement in 
microarray studies (Nadon, 2002; Giorgi, 2010).  Despite this, simply increasing 
experimental replication cannot maximize the accuracy of measurement in such 
studies, as microarray analyses have numerous systematic variance components 
and yield data with magnitude-dependent signal variation.  Also problematic are 
that these experiments involve an extremely large number of variables and yield 
data that often do not fit a normal distribution.   
 Some of these statistical issues can be addressed through data 
transformation, data processing (i.e. normalization) and data filtering.  For 
example, an important rule for microarray studies is to log transform [e.g. 
log2(sig1/sig2)] the data, as this makes variation in signal ratios more 
independent of signal magnitude, reduces distribution skew, and provides a more 
realistic sense of data variability (Alba, 2004; Giorgi, 2010).  Specifically, a log2 
transformation is often used because it converts the expression values to an 
intuitive linear scale that represents twofold differences (Alba, 2004). 
Reproducibility 
 Most types of microarrays give highly reproducible within-platform 
measurements when operating within their range of sensitivity.  Because of this, 
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oligonucleotide arrays (Affymetrix, Agilent and Codelink) seem to perform better 
than cDNA microarrays, generally providing correlation coefficients of above 0.9 
in technical replicates using the same array type (Alba, 2004; Giorgi, 2010).  
However, if the same sample is hybridized on different array types (i.e. Affymetrix 
HG_95Av_2 vs. Affymetrix HG_U133), the correlation coefficients may be lower 
because the same genes may be represented by different sets of probes in the 
two arrays (Verducci 2006).  On platforms such as cDNA microarrays or the 
Mergen platform, the technical reproducibility may also be substantially lower.   
 Numerous cross-platform reproducibility studies have identified two main 
problems with microarray experiments.  Firstly, microarrays do not accurately 
measure genes expressed at low levels (Alba, 2004; Giorgi, 2010).  Thus, 
exempting these genes from the study would improve the correlation between 
different platforms.  Another problem is that not all probes created for specific 
genes perfectly match the targeted genes. This could possibly be addressed by 
re-mapping the probe sequences and calculating expression values using only 
those probes that have the appropriate sequence for the genes they are 
supposed to represent (Verducci 2006; Nadon, 2002). 
Thus, data from different platforms cannot easily or confidently be 
compared or merged when looking at simply the expression levels of individual 
genes. The degree of agreement among different platforms improves 
substantially when instead the results are examined from the perspective of the 
biological process or molecular functions involved (functional profiling).   
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Statistical issues 
A major issue with microarray studies is the final statistical treatment of 
the results, which can be extremely vulnerable to interpretation and biases. 
Random chance alone would predict that a fraction of each dot on the chip are 
“significant” (if traditionally accepted confidence intervals are used (i.e. P < 0.05)) 
by paired t-test—in other words, there would be a large number of false positives 
(Giorgi, 2010; Verducci 2006).  Are these all due to random chance, or could 
there be a subset of truly changed transcripts? 
Bypassing this issue of multiple testing can be accomplished in different 
ways.  One could produce and use sub-arrays containing only those probes that 
correspond to particular genes of interest and genes that are thought to have 
differential expression.  A more conservative solution is to use a statistical 
correction that controls the family-wise error rate— the probability of 
accumulating one or more false positives in an experiment that involves multiple 
testing (Alba, 2004; Giorgi, 2010; Verducci 2006).  The two main multiple test 
correction methods are Bonferroni (most stringent) and Benjamani–Hochberg, 
which both serve to control for false discovery rate (FDR).  FDR statistics provide 
an estimate of how many false positives exist among all the genes initially 
defined as being differentially expressed and thereby allow one to establish a 
criterion for differential expression based on the number of acceptable false 
positives. (Alba, 2004; Verducci 2006; Nadon, 2002).  This often follows an 
analysis of variance (ANOVA) or Principal Components Analysis (PCA) to 
identify and minimize sources of variation.  Such FDR correction is not yet 
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ubiquitous in microarray studies, and this deficiency can partly account for the 
high rate of irreproducible results with microarray technology.  Some authors 
have gone so far as to conclude that most published gene array work is simply 
invalid (Alba, 2004).  
Variance and Sample Size 
Also important is the minimization of variance.  Variance arises from 
technical features (RNA isolation and handling, chip-to-chip, hybridization 
conditions, scanner characteristics, etc) and biological features (animal to animal, 
experimental conditions, etc).  It is essential to keep the variance down and the 
size of samples up, for problems also arise if an inadequate number of samples 
or arrays is used in the experiment (Giorgi, 2010; Nadon, 2002).  In order to have 
significant results, the study design must allow for sufficient arrays.   
 
Epstein Barr Virus 
The Epstein-Barr virus (EBV) is a ubiquitous human gamma herpesvirus, 
also known as human herpesvirus 4 (HHV-4). The principal target cells for EBV 
infection are human primary B-lymphocytes, but the virus can also infect other 
lymphocytes and epithelial cells.  It confers upon normal lymphocytes the ability 
to proliferate indefinitely; this process, called immortalization, is crucial to the 
pathogenesis of EBV infections (Kuppers, 2003). 
The EBV establishes a latent infection in its host that periodically 
reactivates. When establishing a latent infection, the virus progresses through 
three transcriptionally distinct forms of latency, known as latency I, II, and III.  
The EBV utilizes six different viral proteins in order to establish and maintain an 
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infection:  Epstein-Barr Virus Nuclear Antigen (EBNA) 1, 2 and 3 along with the 
Epstein-Barr Virus Nuclear Antigen Leader Protein (EBNA-LP) 1, 2A and 2B. The 
latent programs reprogram and subvert infected B-lymphocytes to proliferate and 
bring infected cells to the sites where the virus persists (Ali, 2009; Takacs, 2009). 
The virus can later enter a productive lytic infection, causing proliferation 
of the host cells (Park, 2008). Given the initial absence of host immunity, the lytic 
cycle produces large amounts of virus to infect other (presumably) B-
lymphocytes within the host. Eventually, when host immunity develops, the virus 
persists by turning off most (or possibly all) of its genes, only occasionally 
reactivating to produce fresh virions.  A balance is eventually struck between 
occasional viral reactivation and host immune surveillance removing cells that 
activate viral gene expression (Gratama, 1998). 
The virus was identified in 1970 as the first human tumor virus—a virus 
whose genome is present in the tumor cells of a given entity in vivo and that has 
strong transforming potential in vitro (Bornkamm, 2009).  The EBV was first 
characterized in 1964 from cell lines derived from Burkitt’s lymphoma (BL), a B-
cell derived childhood malignancy that is endemic in Central and tropical Africa 
(Klein, 2010).  Further research has revealed that about 90% of the population 
worldwide is infected with the EBV during their lives. In the US, as many as 95% 
of adults between the ages of 35 and 40 have been infected (Kuppers, 2003).     
Humans become susceptible to the EBV at birth, when maternal antibody 
protection is lost.  In the Central African population, the virus appears to be 
transmitted early in life and is a major causative agent of endemic BL in children 
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in equatorial Africa (Thorley-Lawson, 2008).  It is responsible for about 95% of 
the cases in Central Africa, 40 to 50% of the cases in HIV-infected individuals 
and 10 to 20% of the sporadic cases across the world (Bornkamm, 2009).  BL is 
often seen associated with HIV and AIDs and other immunodeficient cases, as 
the EBV infection generally subsides in immunocompetent individuals. 
The EBV is transmitted significantly earlier in life in the U.S. and Europe, 
where seroconversion is often delayed to adolescence (Bornkamm, 2009).  
When infection with the EBV occurs during young adulthood, it causes infectious 
mononucleosis 35% to 50% of the time (Klein, 2010).  The virus has also been 
characterized as a causative agent in nasopharyngeal carcinoma (NPC), a 
lymphoepithelial tumor highly prevalent in South China (Bornkamm, 2009; Henle, 
1970; Lin, 2004).   
The EBV has also been associated with other diseases, such as Hodgkins 
lymphoma (Cader, 2010; Mwakigonja, 2010), non-Hodgkin lymphomas (usually 
B-cell lymphomas in people infected with the HIV virus; Mwakigonja, 2010; 
Bertrand, 2010), rare cases of T-cell lymphomas (Mwakigonja, 2010; Park, 2010) 
post-transplant lymphoproliferative disease (PTLD; Stojanova, 2010), and rare 
hematologic conditions (Jin, 2010). 
In addition to its associations with diseases, the EBV is also a vital 
element in creating cell lines for research.  EBV-immortalized B cell lines (LCLs) 
are a valuable source for almost unlimited amounts of DNA from almost any 
individual. This distinct ability of the EBV to cause cells to continually proliferate 
has made the virus invaluable to research in many scientific fields.  
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Although the molecular mechanisms of the infection and immortalization of 
cells by the EBV have been long-studied, we are still far from having an 
adequate understanding of these processes.  Due to the importance of the EBV 
as both an infectious, malignant agent and as a vital element in creating cell lines 
for research, it is crucial to understand the genetics and molecular cell biology of 
the EBV infection and immortalization processes.  
The conduction of a whole transcriptomic expression analysis between the 
two cell states has provided insight as to how the EBV alters the B cell’s 
transcription activity and thus the mechanisms the virus utilizes to maintain 
control over and replication of its host cell. 
 
Specific Aims of Research 
 This study set out to detail the extent to which the EBV changes the cell 
machinery through gene regulation. The overall aim of this thesis research was 
to investigate how the EBV affects the gene expression in immortalized B cells 
by comparing the expression profiles of primary and EBV-immortalized B cells.  
Two specific questions were addressed: 
1) Are any genes differentially expressed between normal B cells and 
those that have been immortalized with the EBV? 
2) If there are genes whose expression is significantly altered after 
immortalization, what sorts of pathways do these genes fall into?  What 
do these pathways elucidate about the EBV immortalization process? 
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To answer these questions, we examined the whole transcriptome from 
two independent studies on different Affymetrix platforms:  Katia Basso et al [25-
27] and Laura Pasqualucci et al. [27,28]. Our analyses identified 4,366 probe-
sets corresponding to 1,598 genes that have significantly different patterns of 
expression between immortalized and primary B-cells.  We further showed 
significant enrichment of these genes into 168 pathways. 
 
METHODS 
Figure 1 summarizes the experimental approach used in this thesis 
research.  
 
 
 
Figure 1.  Flowchart of the experimental design. 
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Search Terms: 
NCBI/ PubMed was queried utilizing the following search terms EBV 
immortalization; returned 362 publications, EBV and B-cell; returned 5401 
publications, EBV and B-cell expression, had 2103 returned publications, and 
EBV and B-cell expression and immortalization returned 159 publications. None 
of these, however, specifically related to perturbations in gene expression 
patterns and levels between IM and Non-IM B- cells. 
 
Obtaining Expression Data 
In order to obtain microarray expression data for IM and Non-IM B-cell, we 
queried and searched through GeneExpressionOmnibus, known as GEO 
Database.  This is a public functional genomics data repository that has array- 
and sequence-based data, such as from gene expression microarrays, single 
nucleotide polymorphisms (SNP) arrays, next-generation sequencing and protein 
arrays (Barrett, 2006).  Such data are made available as often the journal in 
which one publishes requires deposit of microarray data to a repository like GEO.  
We searched for datasets that had mRNA microarray expression data for 
a large sample of primary, Non-IM B cells and EBV-IM B cells.  We were able to 
find two such experimental studies:  
Study 1) Performed by Laura Pasqualucci et al. on the Affymetrix Human 
Genome-U133 Plus-2 arrays.  The sequences from which these probe sets were 
derived were selected from GenBank®, dbEST, and RefSeq.  The array gives 
complete coverage of the human genome, for analysis of over 47,000 transcripts.  
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This dataset contained microarray data of normal, transformed and 
experimentally manipulated human B cells related to the germinal center 
structure. 
Study 2) Performed by Katia Basso et al (GSE2350) on the Affymetrix 
U95Av2 datasets.  The Human Genome U95 (HG-U95) set, consisting of five 
GeneChip arrays, contains almost 63,000 probe sets interrogating approximately 
54,000 clusters derived from the UniGene database (Build 95). 
This study by Basso et al. had 35 different types of EBV-LCL, each with 
their own array.  There were five different LCLs.  One type, of which there were 
six samples, was an LCL with a conditional EBV mutant caused by expression of 
ER-EBNA2 chimeric fusion protein.  It was engineered with the metallothionein 
conditional expression vector.  Cells were treated with CdCl2 [5 uM] for 12 h. 
Targets were produced starting from 6 ug of total RNA following standard 
Affymetrix protocol.  
 Another type of LCL used by Basso et al., of which there were six 
samples, had a conditional EBV mutant caused by expression of ER-EBNA2 
chimeric fusion protein.  It was engineered with a mt-BCL6 conditional 
expression vector.  Cells were treated with CdCl2 [5 uM] for 12 h.  Targets were 
produced starting from 6 ug of total RNA following standard Affymetrix protocol. 
 The third type of LCL, of which there were six samples, had a conditional 
EBV mutant caused by expression of ER-EBNA2 chimeric fusion protein. It was 
engineered with a tetracycline repressed MYC expression vector. Basso et al. 
cultured the cells in the absence of tetracycline and estrogen for 24h. Targets 
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were produced starting from 6 ug of total RNA following standard Affymetrix 
protocol. 
 The fourth type of LCL, of which there were six samples, had a conditional 
EBV mutant by expression of ER-EBNA2 chimeric fusion protein. It was 
engineered by Basso et al. with a tetracycline repressed MYC expression vector. 
Cells were cultured in the presence of tetracycline [1ug/ml] and the absence of 
estrogen for 24h. Targets were produced starting from 6 ug of total RNA 
following standard Affymetrix protocol. 
 The fifth type of LCL, of which there were 5 samples, had a conditional 
EBV mutant caused by expression of ER-EBNA2 chimeric fusion protein. It was 
engineered with a tetracycline repressed expression vector. Cells were cultured 
in absence of tetracycline and of estrogen for 24h. Targets were produced 
starting from 6 ug of total RNA following standard Affymetrix protocol. 
 In addition, Basso et al. used a CB33 cell line, an EBV-immortalized 
lymphoblastoid cell line, a Daikiki EBV-immortalized lymphoblastoid cell line, an 
IARC3043 EBV-immortalized lymphoblastoid cell line, a NC6 EBV-immortalized 
lymphoblastoid cell line and a RD EBV-immortalized lymphoblastoid cell line. 
 
From GEO, we downloaded the raw data files in the Affymetrix CEL 
format, which required subsequent unzipping and conversion to readable 
formats. 
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Normalization and Noise Reduction: 
We applied RMA normalization independently to each array platform and 
filtered based on “Present Call” detection rates.  Detection call methodology 
(DCM) reveals the types of transcripts that are present or absent within samples 
(Archer, 2010). The DCM is typically used on a single array to answer whether a 
transcript of a particular gene is present or absent in a sample.  In this study, we 
filtered to include only probe sets that had Present Calls across all samples to be 
compared. 
For the first study (n=136), out of the 54,675 probe sets, 13,513 had 
Present Call across all samples. The second study did not have Present Call 
information. 
 
Statistical Analyses: 
Differentially expressed probe sets were identified using one-way ANOVA 
(false discovery rate of 0.05, t-test with unequal variance and Benjamini and 
Hochberg False Discovery Rate multiple testing correction).  We independently 
determined the significantly different probe sets between IM and Non-IM in each 
data set.  We intersected these two probe set lists and removed any that a) had 
discordant direction in the intensity covariates between the two lists (i.e. 
Difference in UP or DOWN expression) and b) had a gene in one list that was not 
in the other. 
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Pathway Analyses:  
Ingenuity Systems Pathway Analysis (IPA) software program was used to 
conduct the pathway analysis.  IPA lets researchers search for information on 
genes, proteins, chemicals, drugs, and reagents.  Resulting information can be 
used to build pathway models.  The interactions in these pathways are generated 
by an up-to-date search of the published literature concerning the particular 
genes and proteins (Ganter, 2008).  IPA will automatically query all available 
credible research and build the pathways based on these findings. 
The probe sets found to have differential expression were loaded into IPA 
and mapped to corresponding genes.  Using software features, these genes 
were enriched in different significant canonical pathways (Appendix 1). 
 
RESULTS 
Search Terms 
We conducted queries in NCBI/PubMed to ensure that our study had not 
yet been previously performed.  Our goal was to identify any previous studies 
that had compared the whole transcriptome of Non-IM B-cells to EBV-IM B-cells. 
Our extensive queries showed that there is no publication returned in NCBI 
elucidating whole transcriptome perturbations between primary lymphocytes 
compared to the EBV immortalized lymphoblastoid cells.   
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Significantly Different Probe Sets: 
We applied One-Way ANOVA independently to the two different data sets. 
We identified 2600 probe sets in the U133 study and 2029 probe sets in the 
U95A study, for a combined 4,366 total probe sets that were significantly different 
between IM and Non-IM. After expression direction correction there were 2440 
probes identified for further analyses. 
 
Pathway Analyses: 
The 2440 probe sets were up-loaded into Ingenuity and mapped to 2438 
probe sets, corresponding to 1,598 genes.  These genes were enriched in168 
different significant canonical pathways (Appendix 1).  The top canonical 
pathway associated with the genes was B-cell receptor signaling (p-value 6.17e-
09; Figure 2).  The significant p-value cut-off was at 0.05 or 5e-02.   
Also among the enriched pathways were:  Myc Mediated Apoptosis 
Signaling (1.74e-04; Figure 3), NF-kB Signaling (7.08e-04; Figure 4), CD28 
Signaling (1.26e-7; Figure 5), Role of NFAT in Regulation of the Immune 
Response (5.25e-8; Figure 6) and Cell Cycle Regulation by BTG Family Proteins 
(3.31e-4; Figure 7).   
All pathways and their component molecules are listed in Appendix 1. 
 
 
 
Huberts	   26	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2: B-cell receptor signaling pathway enrichment of the 1598 gene list of differentially expressed genes 
between the Immortalized and Non-Immortalized B-cells. Green are down regulated genes in IM compared to 
Non-IM and red are up regulated. The gene symbols with mixed green and red are groups of genes shown in a 
combined gene group in the pathway (e.g. MEKK consists of MAP3K1   , MAP3K14   , MAP3K5   , MAP3K7   , 
MAP3K8    ).  
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Figure 3: Myc Mediated Apoptosis Signaling (1.74e-04) 
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Figure 4:  NFkB Signaling (6.81e-04) 
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Figure 5:  CD28 Signaling Pathway (2.95E-06) 
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Figure 6.  Role of NFAT in Regulation of the Immune Response (5.25e-8) 
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Figure 7. Cell Cycle Regulation by BTG Family Proteins. (p-value 3.31e-4) 
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DISCUSSION 
Genes of Interest 
WRN 
In examining the list of 1,598 genes that were significantly differentially 
expressed, of note was Werner syndrome Helicase (WRN), which was within the 
top three of greatest fold change.  This was highly intriguing as it confirmed 
results from an experiment previously conducted by our lab.  WRN is a 3′ → 5′ 
exonuclease and helicase.  It is mutated in Werner Syndrome (WS), which is a 
recessive genetic disorder associated with a complex premature ageing 
phenotype (Eller, 2006; Multani, 2007).  Symptoms include aberrant telomere 
maintenance, chromosomal rearrangements and predisposition to malignancy.  
Much of the pathophysiology associated with WS, including the rapid onset of 
cellular senescence, early cancer onset and premature aging, can be attributed 
to a defect in telomere maintenance.  Telomeres cap the ends of eukaryotic 
chromosomes and prevent them from being recognized as DNA breaks (Eller, 
2006; Multani, 2007).  WRN appears to play a major role in genome stability, 
particularly during DNA replication and telomere metabolism (WRN at telomeres: 
implications for aging and cancer) and in the initiation of DNA damage responses 
after telomere disruption (Eller, 2006; Multani, 2007).  
WRN has also been shown to modulate the efficiency of EBV 
immortalization of LCLs (Kohane, 2009; Sugimoto, 2004), possibly through its 
role in the stabilization of telomeres and telomerase and the immortalized 
genome (Kohane, 2009; Lebel, 1998).  The expression of WRN (and the other 
genes in the previous immortalization network) was found in the previous 
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experiment to be highly correlated with EBV titer in B cells. This study strongly 
suggested that WRN DNA helicase is used in the immortalization of LCLs 
transformed by the EBV (Eller, 2006). These results together with other studies 
support the view that WRN helicase contributes unlimited cell proliferation 
probably by keeping the genome stable in immortal cells.  A body of evidence 
has now accumulated implicating that WRN helicase plays an essential role in 
maintaining telomeres together with telomerases (Shiratori,1999; Kawabe, 2000). 
The fact that the WRN gene was found to be significantly up-regulated in 
IM B-cells as compared to the primary, Non-IM B-cells in our current study 
supports our previous work and the theory that WRN is utilized by the EBV in 
order to maintain immortalization of the B cell.  
Currently no other genes found to be significantly differentially expressed 
have been looked at in depth.   
 
Pathways 
B-cell receptor signaling (BCRS) Pathway: 
The top canonical pathway associated with the 1,598 gene list was B-cell 
receptor signaling, with a p-value of 6.11e-9 (Figure 2). Within the BCRS 
pathway there are 16 kinases (Lyn, CSK, Syk, SHP2, PI3K, SHIP, Btk, AbI1, 
MEKK, AKT, MEK1/2, GSK3, IKK, ERK1/2, JNK1/2, p38 MAPK) that are 
differentially expressed between Non-IM and IM.  Scientists have independently 
shown previously that many of these 16 kinases are directly regulated by EBV 
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proteins (Sanderson, 2010; Tauzin, 2010; Ke, 2009; Hermiston, 2009; Cao, 
2010; Castro, 2009). 
The Lyn kinase was found to be on average 1.65 fold up regulated in the 
BCRS pathway. The kinase that can directly inactivate Lyn, CSK homologous 
kinase (CHK), is down-regulated in the pathway.  LMP2A is a tyrosine kinase 
substrate and an EBV integral plasma membrane protein that associates with 
LMP1.  LMP2A associates with src family protein tyrosine kinases, particularly 
lyn kinase (Sanderson, 2010).  This LMP2A association with B-lymphocyte src 
family tyrosine kinases is likely to be an important pathway in EBV's effects on 
cell growth. 
Lyn directly regulates Syk, which is down regulated with an average fold 
change of 3.748 in the BCRS pathway (Sanderson, 2010; Tauzin, 2010; Ke, 
2009).  Syk is a non-receptor type Tyr protein kinase that is widely expressed in 
hematopoietic cells and is involved in coupling activated immunoreceptors to 
downstream signaling events that mediate diverse cellular responses, including 
proliferation, differentiation, and phagocytosis (Sanderson, 2010). It is thought to 
be a modulator of cell growth and a potential tumor suppressor.  This interaction 
between the EBV LMP2A, Lyn and Syk demonstrates a possible way that the 
EBV shuts down potential suppression of proliferation, a necessary step for 
successful immortalization (Sanderson, 2010; Ke, 2009). 
In addition, the Lyn kinase directly regulates CD19, CD22, CD79A and 
CD79B (Sanderson, 2010; Tauzin, 2010; Ke, 2009).  An additional BCR is down-
regulated in IM cells—CD45.  These membrane receptors are critical in the B 
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cell’s ability to not only present antigens, but also to communicate to the rest of 
the immune system, (Hermiston, 2009) particularly with Helper T cells, which aid 
in the activation of B cell antibody activity.  The down-regulation of these 
receptors would aid in the EBV’s ability to continue proliferation throughout the 
body without detection by the body’s immune system. These findings are in line 
with previous studies demonstrating EBV latency and down regulation of BCRs in 
immortalized B-cells (Hermiston, 2009).  
In the BCRS pathway, c-Jun N-terminal kinase (JNK)—also known as 
mitogen-activated protein kinase 8 (MAPK8)—was upregulated.  This is a kinase 
that binds and phosphorylates the transcription factor c-Jun on serines 63 and 
73, causing the induction of cell death (Cao, 2010).  While c-Jun itself has no 
significant fold-change difference, the fact that its regulator, JNK, has a positive 
fold change difference in IM B cells, is puzzling, as this would promote an 
apoptotic response.  Why this regulation appears to be occurring in the 
immortalized B cells brings up several important issues with the pathways.   
The fact that potential apoptotic activity is being up-regulated in the 
immortalized B cell may indicate that the cell is finished with a state of active 
proliferation and is turning off further growth activity.  A limitation of the study is 
that the expression profiles and the subsequent pathways offer only a snapshot 
of mRNA expression activity at a given point in time for the immortalized B cells, 
rather than a big-picture of all stages of immortalization.  The expression patterns 
change throughout the infection and immortalization process.  Because of this, 
one cannot claim all stages of the immortalization process to be equal.  The 
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activation of this apoptotic activity in the pathway suggests that the B cells may 
have been profiled near the end of a proliferation phase; however, this 
information is not precisely known.   
The pathway also brings to light a limitation of pathways themselves.  
Though the pathways are useful in visualizing and understanding interactions 
within a given biological function or context, they by no means capture the full 
dimensional complexity of interactions occurring between and amongst genes, 
proteins and the virus.   
Also of note is that normal activation of the BCR leads to the stimulation of 
nuclear factor kappa B (NFκB) and its pathway.  Central to BCR signaling via NF-
kB is Bruton's tyrosine kinase (BTK), the adaptor B-cell linker (BLNK) and 
phospholipase C gamma 2 (PLCγ2) (Castro, 2009).  BLNK is phosphorylated on 
BCR activation and serves to couple the tyrosine kinase SYK (-5.4 fold down 
regulated in IM compared to Non-IM in our study) to the activation of PLCγ2.  
The complete stimulation of PLCγ2 is facilitated by BTK (-1.5fd) (Castro, 2009). 
Stimulated PLCγ2 triggers the DAG and Ca2+ mediated activation of 
Protein kinase (PKC) which in turn activates IγB kinase (IKK) consisting of 
(IKBKB(-2.4fd) and IKBKG (-1.3fd)) and thereafter NFκB (Castro, 2009).  In 
addition to the activation of NFκB, BLNK also interacts with other proteins like 
VAV and GRB2 (-1.5fd) resulting in the activation of the mitogen activated protein 
kinase (MAPK) pathway (Castro, 2009).   
However, the abundance of IM down-regulated genes enriched in the NF-
kB pathway provides further evidence of this pathway being down regulated by 
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the EBV reducing downstream effects of the NF-kB apoptotic responses in 
support of EBV latency and immortalization of B-cells.  
NF-kB Signaling Pathway: 
The NF-kB pathway has a p-value of 6.81e-04 (Figure 4).  NF-kB is a 
transcription regulator that, when activated, translocates into the nucleus and 
stimulates the expression of genes involved in a wide variety of biological 
functions (Thompson, 2010; Staudt, 2010).  Inappropriate activation of NF-kB 
has been associated with a number of inflammatory diseases while persistent 
inhibition of NF-kB leads to inappropriate immune cell development or delayed 
cell growth (Thompson, 2010; Staudt, 2010). 
The tumor necrosis factor receptor-associated factor 5 (TRAF5) has an 
average positive fold change of 3.997.  TRAF proteins are associated with and 
mediate signal transduction from members of the TNF receptor superfamily (Xie, 
2009). Activation of TRAF5 (TRAF signal cascade) has been found to suppress 
oriP activity (Shirakata, 2001).   
Latent EBV is maintained by the virus replication origin (oriP), a 1.7-kb 
region of the EBV chromosome that interacts with the viral EBNA-1 protein and 
supports the replication and stable maintenance of plasmids in human cells 
(Shirakata, 2001).  oriP guarantees plasmid stability by mediating two basic 
functions: replication and segregation of the viral genome.  Activation of the 
TRAF5 cascade would appear to have detrimental effects to the EBV’s ability to 
replicate and proliferate in the B cells.   
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Of interest are the downstream, final effects of this pathway, particularly 
the intense regulation of the tumor-suppressor transcription factor p53 by no less 
than seven different proteins, five of which have significant differential 
expression.  The examination of the three main proteins—HDAC, GSK3beta and 
p300/CBP—yields interesting insights into possible mechanisms used by the 
EBV along with further analysis of the limitations of the pathways. 
Histone deacetylase (HDAC) was found to have an average positive fold 
change of 2.2825 in IM B cells.  HDAC is a component of the histone 
deacetylase complex, which plays a key role in the regulation of eukaryotic gene 
expression (Kurosawa, 2010).  HDAC interacts with retinoblastoma tumor-
suppressor protein and deacetylates p53, modulating its effect on cell growth and 
apoptosis (Kurosawa, 2010).  HDAC’s regulation of p53 tumor-suppressor 
activity could help to allow the continued proliferation of the B cells. 
Glycogen synthase kinase-3beta (GSK3beta) was found to have an 
average positive fold change of 1.6415 in IM B cells.  This kinase is a central 
figure in Wnt signaling, in which its activity is controlled by regulatory binding 
proteins.  It has also been shown to be directly activated by p53 in response to 
DNA damage, allowing these proteins to act in concert to regulate subsequent 
cellular responses (Naderi, 2004). Thus, GSK3beta may be aiding to activate p53 
DNA damage responses. 
The p300-CBP coactivator family is composed of two closely related 
transcriptional co-activating proteins (or coactivators): p300 (also called EP300 or 
E1A binding protein p300) and CBP (also known as CREB binding protein or 
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CREBBP).  Both p300 and CBP interact with numerous transcription factors and 
act to increase the expression of their target genes (Zhao, 2003).  Substantial 
evidence points to a critical role for the p300/CBP coactivators in p53 responses 
to DNA damage.  p300/CBP and the associated protein P/CAF bind to and 
acetylate p53 during the DNA damage response, and are needed for full p53 
transactivation as well as downstream p53 effects of growth arrest and/or 
apoptosis (Zhao, 2003).  Through physical interaction with p53, p300/CBP can 
both positively and negatively regulate p53 transactivation, as well as p53 protein 
turnover depending on cellular context and environmental stimuli, such as DNA 
damage.  
p300/CBP’s down-regulation in the pathway may contribute to 
suppression of p53’s ability to initiate apoptosis, thereby aiding further 
proliferation and immortalization of the B cell.  However, as p300/CBP can also 
have positive regulatory effects on p53, we cannot assume that it is hindering its 
activity.  As the expression of p53 itself did not change significantly in IM as 
compared with Non-IM B cells, no solid conclusions can be drawn about 
p300/CBP’s role. 
The activity of p53 is thus being potentially activated by GSK3beta, 
suppressed by HDAC and either up or down regulated by p300/CBP.  These 
results are seemingly contradictory but actually serve to illuminate again the vast 
complexities of protein and gene interactions and emphasize the dynamic picture 
of cellular activity.  Additionally, it draws attention to the question as to which 
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parts of these pathways are truly being directly affected by the EBV and which 
are part of normal B cell activity. 
The examination of the TRAF5 cascade along with the activity of HDAC, 
GSK3beta and p300/CBP leads to a potentially confusing conclusion.  While 
immortalized B cells would be expected to have considerable proliferative 
activity, suppression of apoptotic pathways and up regulation of pathways that 
aid EBV replication, the study finds that this is not always the case.  In reality, we 
find a complex mixture of activity, which may suggest that expression is the result 
of an analysis early on in the immortalization process, when the EBV has not yet 
gained total control over the cell.  Contrastingly, the results may suggest that the 
EBV never indeed gains total control over the B cells it infects and must 
constantly fight with, or simply is able to allow, such activities from tumor 
suppressor proteins and elements that promote apoptosis.  Further examination 
of these possibilities is found at the end of the Discussion. 
Myc-Mediated Apoptosis Signaling Pathway 
The Myc Signaling pathway had a p-value of 1.74e-04 (Figure 3) with Myc 
itself having an average fold change of 3.22 in IM B cells.  The protein encoded 
by this gene is a multifunctional, nuclear phosphoprotein that plays a role in cell 
cycle progression, apoptosis and cellular transformation (Ouansafi, 2010).  It 
functions as a transcription factor that regulates transcription of specific target 
genes.  Mutations, over-expression, rearrangement and translocation of this 
gene have been associated with a variety of hematopoietic tumors, leukemias 
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and lymphomas, including Burkett’s lymphoma, earning Myc the label of an 
oncogene (Sluss, 2010; Ouansafi, 2010). 
In the pathway determined by this study, FAS was found to have an 
average fold change of 3.5934 in IM B cells. This receptor has been shown to 
activate NF-kB, MAPK3/ERK1, and MAPK8/JNK. 
FAS is member 6 of the tumor necrosis factor receptor super-family and is 
now officially known as TNFRSF6 (previously APO-1, APT1, and CD95). The 
receptor contains a death domain and has been shown to play a central role in 
the physiological regulation of programmed cell death and also has been 
implicated in the pathogenesis of various malignancies and diseases of the 
immune system (Jaberipour, 2010; Kaku, 2009). The interaction of this receptor 
with its ligand allows the formation of a death-inducing signaling complex that 
includes Fas-associated death domain protein (FADD), caspase 8, and caspase 
10.  Interaction of FADD with the receptors unmasks the N-terminal effector 
domain of this protein, which allows it to recruit caspase-8, and thereby activate 
the cysteine protease cascade.  The autoproteolytic processing of the caspases 
in the complex triggers a downstream caspase cascade, leading to apoptosis 
(Jaberipour, 2010; Kaku, 2009).  
While FAS is highly up-regulated in IM B cells, FADD is unchanged and 
Caspase-8 is down-regulated, with an average fold change of -2.028.   
The snapshot of this pathway gives a complicated picture of the activity in 
the cell during immortalization.  While part of the FAS pathway for apoptosis is 
up-regulated, other aspects are down-regulated.  In addition, the proto-oncogene 
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Myc is strongly up-regulated in the cell.  Again, while this pathway gives insight 
into the complexities of the immortalization process, it is limited in that it cannot 
detail the dynamic interactions of the proteins over time. 
CD28 Signaling in T-Helper Cells 
The CD28 pathway had a p-value of 2.95E-06 (Figure 5). 
T helper cells (Th cells) are a sub-group of lymphocytes that play a key 
role in the immune response (Loskog, 2006). Th cells cannot kill infected host 
cells or pathogens, but rather are involved in directing other immune cells [37-40] 
and are necessary in the activation of B cells, which produce antibodies to fight 
off pathogens.  In order to become activated and differentiate into a functional 
state, a B-cell must first bind an antigen and then receive the proper signal from 
the helper T cells; without both of these steps, the B cells remain useless to the 
immune system (Loskog, 2006). 
 Our pathway appears to indicate that the helper T cells are being affected 
in multiple ways, thus possibly impeding them from activating other immune 
responses.  Firstly, a protein called CD45 is down-activated.  This phosphatase 
works with the intracellular kinases on the TCR, CD3 and CD4, in order to 
produce an important, initial signal in the Th cell, Signal 1 (Altin, 1997).  Its down-
regulation thusly hinders or prevents the first important pro-activation signals in 
the Th cells. 
 Further downstream and also of importance is the fact that the 
transcription factor NFAT is down-regulated. NFAT is a critical component of the 
signaling pathway that regulatesIL-2expression (Haylett, 2009).  The production 
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of IL-2 is necessary for proliferation of Th cells once they have been activated 
(Haylett, 2009).  The down-regulation of NFAT, therefore, hinders the production 
of IL-2 and thus restricts the proliferation of Th cells. 
 These results are intriguing, as they pertain specifically to a Th cell 
pathway, whilst the study looked only at B cells.  The emergence of this pathway 
in the results brings up several possibilities and issues.  It is possible that the B 
and Th cell have this pathway in common and the pathway analysis software 
simply labeled it as the Th cell one.  While possible, this also brings up issues as 
to the credibility of the generated pathways and their titles.  In addition, this 
reveals problems with the limitations of the pathways.  Though based on the 
gene expression profiles of the study, the pathways may not reflect the true 
interactions of the genes.  While a potentially accurate visualization of some 
activity, the very creation of the pathway limits the possible visualization of gene 
and protein grouping and interactions. 
Role of NFAT in Regulation of the Immune Response 
The NFAT pathway had a p-value of 5.25e-8 (Figure 6).  Nuclear factor of 
activated T-cells, cytoplasmic, calcineurin-dependent (NFAT) is a member of the 
nuclear factors of activated T cells DNA-binding transcription complex (Haylett, 
2009).  This complex consists of at least two components: a preexisting cytosolic 
component that translocates to the nucleus upon T cell receptor (TCR) 
stimulation and an inducible nuclear component.  The protein plays a role in the 
regulation of gene expression in T cells and immature thymocytes. 
 NFAT induces and activates the ZP-promoter region of the ZEBRA EBV 
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immediate-early transcription factor ZEBRA (BZLF1, Zta, Z, EB1), causing 
activation (Liu, 1997).  This induces a cascade of expression of over 50 viral 
genes, causing the switch from latent to lytic infection. 
 NFAT’s strong down-regulation in the pathway allows the B cell to remain 
in the latent cycle.  In this stage, the B cell can continue proliferation without 
exposing a large amount of viral antigens outside of cells and thereby alert the 
immune system (Liu, 1997).  Control of this pathway would aid the EBV to remain 
in the latent phase for long periods of time without detection by other immune 
cells. 
Myocyte enhancer binding factor 2 (MEF2), has an average negative fold 
change of -1.61 in the pathway.  It is a member of the MADS box transcription 
enhancer factor 2 family of proteins, which play a role in myogenesis, or the 
formation and maintenance of the differentiated state of muscle cells (Liu, 1997). 
The encoded protein has both trans-activating and DNA binding activities. This 
protein may play a role in maintaining the differentiated state of muscle cells.   
During EBV latency, proteins of the MEF2 family are bound to the ZEBRA 
promoter (Haylett, 2009; Liu, 1997).  Latency is determined primarily by a specific 
and local recruitment of class II histone deacetylase (HDAC) by MEF2 to the 
ZEBRA gene promoter. The switch from latency to the lytic cycle could be due in 
part to post-translational modification of MEF2 proteins and changes in the local 
acetylation state of the chromatin.  The strong down-regulation of MEF2 activity 
would contribute to the maintenance of the B cell in the latent stage. 
The non-receptor type Tyrosine protein kinase SYK is again down-
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regulated in this pathway, similarly to the BCRS pathway.  This down-regulation 
is directed by the BCR and leads to the downstream down-regulation of NFAT 
and MEF2.  
Cell Cycle Regulation by BTG Family Proteins 
This Cell Cycle pathway had a p-value of 3.31e-4 (Figure 7).  B-cell 
translocation gene 2 (BTG2) is an anti-proliferative component of the DNA 
damage cellular response pathway and cell cycle control (Winkler, 2010; Zhang; 
2010).  It has tumor suppressor activity similar to that of p53; in fact, BTG2 
expression is sometimes induced through a p53-dependent mechanism.  The 
down-regulation of this protein could allow for continued cellular proliferation, a 
feature that holds true with immortalized cells.       
There are two main up-regulated proteins in the pathway that are 
oncogenic: CDK4, CDK2.  CDK4 (cyclin-dependent kinase) is a catalytic subunit 
of the protein kinase complex that is important for cell cycle G1 phase 
progression.  CDK2 (cyclin-dependent kinase 2) is a catalytic subunit of the 
cyclin-dependent protein kinase complex, whose activity is restricted to the G1-S 
phase, and essential for cell cycle G1/S phase transition (Winkler, 2010; Zhang; 
2010).  The combination of these two proteins aids in continuation of the cell 
cycle and later proliferation of the cells. 
Another up-regulated protein in the pathway is protein phosphatase 2A.  
This is one of the four major Ser/Thr phosphatases and is implicated in the 
negative control of cell growth and division (Zhang; 2010).  Its up-regulation 
would seem to counteract the efforts of the oncogenes in the pathway and work 
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instead toward G1 arrest.   
Like the other pathways, the cell cycle regulation in the IM B cell is not a 
simple story of across-the-board enhanced proliferation and suppression of anti-
growth proteins.  Instead, there exist complicated dynamics within the cells 
during immortalization.  
 As stated throughout the Discussion, there are numerous limitations of this 
study.  Several of these lie in the datasets.  The primary B cells in each dataset 
were not the same cells as the EBV-immortalized ones to which they were 
compared.  This is a major problem, as the differences in expression obtained 
may be attributed to the cells simply being from different people and locations, 
rather than strictly to the EBV immortalization process.  Also, the type of primary 
and IM B cells varied throughout the arrays, as there were different types of 
samples.  This also could have led to skewed results.  
 The generation of the pathways always has deficiencies.  Since the 
pathway analysis program uses published data to construct the gene-gene and 
protein interactions in the pathways, the data are restricted to what has already 
been extensively studied; the pathways thus may be missing important 
interactions that have simply not been characterized yet.  Also, the publications 
queried by the pathway software were not necessarily pertaining to B cell 
experiments.  Thus, the information on the interactions that make up the 
pathways may have come from studies looking at completely different cells and 
situations.  These data cannot necessarily be applied to gene and protein 
interactions in B cells. 
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A main problem with the study is trying to sort out which aspects of the 
differential expression and the pathways are truly directly affected by the EBV 
and which are part of normal B cell activity or due to some other variable.  To 
answer this, more detailed studies are required. 
 
CONCLUSIONS AND FURTHER DIRECTIONS 
 
Conclusions 
 
 This study has potentially elucidated some of the alterations that the EBV 
causes in a B cell’s gene expression after infection and immortalization.  These 
findings hold implications for those who use EBV-immortalized B cell lines for 
experiments.  A full understanding of the immortalization state of B cells is 
necessary in LCL experiments so that the results are not confounded or 
misinterpreted. 
 The pathways allow insight into the mechanisms the EBV uses in order to 
keep the B cells immortalized.  Further studies and characterizations are needed 
to paint the full picture of all of the steps and mechanisms for EBV 
immortalization.  Such information could be used to aid research of EBV-
associated diseases.  Once a full map has been created of the EBV mechanisms 
of infection and immortalization in vivo, steps can be taken to work on vaccines 
or drugs that can aid in the prevention or cure of such diseases. 
 The expression profiles and pathways could also be applied to research 
on similar viruses, such as the Herpes simplex virus 1 and 2 (HSV-1 and HSV-2).  
As these viruses are in the same family as EBV, their structures and infection 
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mechanisms are similar.  Further studies on the EBV infection and 
immortalization processes could elucidate valuable information concerning the 
study of other human herpes virus diseases, or also from viruses from other 
families that are similar. 
 
Further Directions 
Analysis on the rest of the pathways is on-going and will be completed in 
order to generate a more complete picture of the alterations made in the B cell 
after immortalization.  More in-depth examination of the expression profiles for 
primary and IM B cells is required as well.   
Additionally, we are currently collecting peripheral blood samples from a 
cohort in the New England and Atlanta Metro areas in order to conduct our own 
wet-lab experiment characterizing the perturbations in genetic and transcriptomic 
data extracted from B-cells pre and post EBV immortalization.  These data will be 
compared to the current study in order to validate the findings.  This subsequent 
study will strive to eliminate some of the problems encountered in the current 
study.  In the follow-up study, the same primary B cells profiled for expression will 
be immortalized with the EBV, avoiding the prior issue of samples coming from 
different people and places.  The second study will also profile the expression 
levels at different times during the immortalization process, as it is a dynamic, 
rather than static process; this will give a clearer picture of the way the EBV 
alters the cells. 
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APPENDIX 1 
 
Pathway	  Enrichment	  of	  the	  1,598	  Genes	  that	  Are	  Differentially	  
Expressed	  Between	  IM	  and	  Non-­‐IM	  B	  Cells	  with	  Benjamini-­‐Hochberg	  
Multiple	  Test	  Correction	  
Ingenuity	  
Canonical	  
Pathways	  
B-­‐H	  p-­‐
value	   Molecules	  
B	  Cell	  Receptor	  
Signaling	  
6.17E-­‐09	  
RAC2,PIK3CA,MAPK1,NFATC3,POU2F2,SOS2,ABL1,MAP3K5	  
(includes	  
EG:4217),MAPK13,CD79A,PTPRC,IKBKB,IKBKG,MAP3K7,SOS1,CRE
B1,CD22,ATF4,GSK3B,CHUK,MAP2K1,ETS1,PIK3C2B,MAP3K14,CD1
9,CD79B,GRB2,CSK,MAP3K1,RAC1,MAPK9,NFATC1,PPP3CC,INPP5
D,BTK,PTPN11,SYK,LYN,VAV1,PIK3CB,MAP3K8,ELK1	  
Molecular	  
Mechanisms	  of	  
Cancer	  
1.66E-­‐08	  
PRKACB,RAC2,PIAS2,JAK1,MAPK1,SOS2,MAPK13,MYC,PTK2,PAK1,
CASP9,GSK3B,GNA13,HIPK2,PMAIP1,BIRC3,ATM,PIK3C2B,SMAD2,
CREBBP,RAC1,TCF3,RAP1A,APC,DAXX,RHOQ,CCND3,PTPN11,IRS1,
CDK4,ARHGEF6,CYCS	  (includes	  
EG:54205),ARHGEF18,CFLAR,CDK2,FNBP1,FYN,PIK3CA,RALA,PA2G
4,ARHGEF7,GNA11,ABL1,CTNNA1,HIF1A,MAP3K5	  (includes	  
EG:4217),E2F3,RHOH,FAS,EP300,CHEK1,BRAF,MAP3K7,SOS1,E2F5,
ARHGEF2,CASP8,MAP2K1,GRB2,ADCY3,PRKAR2A,MAPK9,BAX,XIA
P,GNAI2,FOXO1,RBPJ,PIK3CB,ELK1,CASP7,CTNND1	  
Citrate	  Cycle	  
1.86E-­‐07	  
SDHA,SDHB,IDH3G,MDH1,ACLY,IDH1,SUCLA2,CS,PCK2,DLST,DLD,I
DH3A,MDH2,FH,ACO1,ATP5G3	  
Huntington's	  
Disease	  
Signaling	  
1.86E-­‐07	  
RAC2,POLR2D,MAPK1,HSPA1A,SGK1,SOS2,GNB5,HSPA5,HSPA4,CA
SP9,POLR2H,TCERG1,ATF4,NAPA,PIK3C2B,HDAC2,HSPA9,CREBBP,
RAC1,ITPR1,GPAA1,ATP5B,POLR2E,CASP2,CYCS	  (includes	  
EG:54205),CAPN7,POLR2I,SDHB,PIK3CA,GNA11,HDAC9	  (includes	  
EG:9734),CASP4,GNG7,EP300,CREB1,SOS1,CASP8,SDHA,UBB,GRB2
,GLS,MAPK9,BAX,GNG5,ZDHHC17,RCOR1,CAPNS1,STX16,PIK3CB,N
COR2,CASP7	  
Protein	  
Ubiquitination	  
Pathway	  
4.17E-­‐07	  
USP24,USP14,PSMD7,USP11,CDC23	  (includes	  
EG:8697),HSPA5,USO1,USP8,PAN2,USP13	  (includes	  
EG:8975),USP10,PSMD14,PSMA2,BIRC3,UBB,UCHL3,PSMB5,UBE2
M,UBE4B,PSME2,PSMC4,PSMD6,PSMD3,PSMD5,PSMA1,UBE3A,U
BE2L6,UBE2D1,SKP1,XIAP,SKP2,PSMD11,PSMC1,CUL2,PSMB2,PSM
D2,PSMA5,ANAPC5,HSP90AA1,PSMD1,BTRC,USP46,SMURF2,USP3
4,TCEB1	  
EIF2	  Signaling	  
4.17E-­‐07	  
EIF2S2,RAC2,PIK3CA,EIF2B4,MAPK1,SOS2,EIF2S1,EIF4G1,EIF2B2,EI
F4E,EIF3B,EIF1AX,PAIP1,EIF5,SOS1,GSK3B,PPP1CA,MAP2K1,PIK3C
2B,GRB2,RAC1,EIF3J,EIF2C2,EIF3C,EIF4A1,PIK3CB,EIF2AK2	  
RAN	  Signaling	  
8.71E-­‐07	  
KPNA3,KPNA5,KPNA6,CSE1L,TNPO1,XPO1,RANBP1,RCC1	  (includes	  
EG:1104),KPNA1,IPO5,RANGAP1	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Regulation	  of	  
eIF4	  and	  
p70S6K	  
Signaling	   1.23E-­‐06	  
RAC2,EIF2S2,PIK3CA,EIF2B4,MAPK1,PPP2R2A,SOS2,MAPK13,EIF2S
1,EIF4G1,EIF2B2,EIF4E,EIF3B,EIF1AX,PAIP1,SOS1,MAP2K1,PIK3C2B
,GRB2,RAC1,EIF2C2,EIF3J,PPP2CB,PPP2R4,EIF3C,IRS1,EIF4A1,PIK3C
B,PPP2R5E,PPP2R1B	  
Glucocorticoid	  
Receptor	  
Signaling	  
1.23E-­‐06	  
PRKACB,RAC2,JAK1,POLR2D,MAPK1,HSPA1A,NFATC3,SOS2,MAPK
13,HSPA5,IKBKB,HSPA4,IKBKG,POLR2H,PIK3C2B,MAP3K14,SMAD2
,CDK7,HSPA9,CREBBP,RAC1,PPP3CC,NCOA3,KAT2B,POU2F1,TAF5,
POLR2E,HSP90AA1,POLR2I,PIK3CA,ICAM1,POU2F2,TAF7,EP300,GT
F2A2,PTGES3	  (includes	  
EG:10728),HSP90AB1,PCK2,MAP3K7,CREB1,SOS1,CHUK,STAT1,MA
P2K1,TAF12	  (includes	  
EG:6883),GRB2,MAP3K1,MAPK9,NFATC1,PIK3CB,NRIP1,NCOR2,EL
K1	  
Role	  of	  NFAT	  in	  
Regulation	  of	  
the	  Immune	  
Response	  
1.45E-­‐06	  
RAC2,FYN,PIK3CA,HLA-­‐
DOA,MAPK1,NFATC3,SOS2,GNA11,GNB5,HLA-­‐
DMB,CD79A,GNG7,CABIN1,IKBKB,IKBKG,SOS1,XPO1,GSK3B,GNA1
3,CHUK,MAP2K1,PIK3C2B,CD79B,CSNK1G2,GRB2,RAC1,NFATC1,P
PP3CC,ITPR1,GNG5,GNAI2,HLA-­‐
DQB1,BTK,CD80,SYK,ITPR3,LYN,HLA-­‐DOB,IKBKAP,PIK3CB,MEF2C	  
Mitochondrial	  
Dysfunction	  
2.95E-­‐06	  
SDHB,NDUFA9	  (includes	  EG:4704),COX10	  (includes	  
EG:1352),COX8A,PDHA1	  (includes	  
EG:5160),NDUFS1,CASP9,PARK7,NDUFAB1,NDUFS6	  (includes	  
EG:4726),UQCRFS1,NDUFS2,GPX4,CASP8,NDUFS4,AIFM1,SDHA,N
DUFV1,NDUFAF1,UCP2,MAPK9,GSR,NDUFV2,ATP5B,NDUFS8,NDU
FA6,TXN2,UQCRC2,CAT,COX5A,CYCS	  (includes	  
EG:54205),CYC1,UQCRC1	  
CD28	  Signaling	  
in	  T	  Helper	  
Cells	  
2.95E-­‐06	  
RAC2,FYN,PIK3CA,HLA-­‐DOA,NFATC3,HLA-­‐
DMB,PTPRC,IKBKB,IKBKG,PAK1,ARPC3,CHUK,MAP2K1,PIK3C2B,GR
B2,CSK,MAP3K1,RAC1,MAPK9,NFATC1,ITPR1,PPP3CC,HLA-­‐
DQB1,CD80,PTPN11,WAS,SYK,ITPR3,HLA-­‐DOB,PIK3CB,VAV1	  
Purine	  
Metabolism	  
7.24E-­‐06	  
POLR2D,TRAP1,NME2,POLB,POLD3,WRN	  (includes	  
EG:7486),IMPDH2,BCKDHA,POLR2H,RUVBL2,RAD51C,ATP5G3,POL
R3C,AMPD3,RP2,POLE2,PSMC4,RRM2,SMARCA5,PSMD6,ADAR,GA
RT,PDE8A,PRPS2,ATP5B,PPP2R4,POLR2E,HPRT1,PFAS,AK2,POLR2I,
PPAT,RFC3,ENTPD4,RUVBL1,ATP5S,POLD4,POLR1C,ADSL,MYO9B,A
DK,POLR3G,ATP6V1G1,ABCD3,DCK,PRIM2,ADCY3,PAICS,CLPX,HSP
D1,RFC5,POLD1,ATIC,RRM1	  (includes	  
EG:6240),PSMC1,GMPS,POLA2,DDX1,AFG3L2	  
Induction	  of	  
Apoptosis	  by	  
HIV1	   7.24E-­‐06	  
MAP3K14,SLC25A13,CXCR4,SLC25A3,MAPK9,MAP3K5	  (includes	  
EG:4217),BAX,DFFA,FAS,XIAP,DAXX,IKBKB,IKBKG,RIPK1,CASP9,CYC
S	  (includes	  EG:54205),IKBKAP,CHUK,CASP8,BIRC3	  
PI3K/AKT	  
Signaling	  
1.48E-­‐05	  
TSC1,RAC2,PIK3CA,JAK1,MAPK1,PPP2R2A,SOS2,MAP3K5	  (includes	  
EG:4217),EIF4E,YWHAQ	  (includes	  
EG:10971),IKBKB,IKBKG,GYS1,HSP90AB1,SOS1,GSK3B,CHUK,RHEB,
MAP2K1,GRB2,RAC1,INPP5D,PPP2CB,FOXO1,PPP2R4,HSP90AA1,
MAP3K8,PIK3CB,PPP2R5E,PPP2R1B	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Production	  of	  
Nitric	  Oxide	  
and	  Reactive	  
Oxygen	  Species	  
in	  
Macrophages	   1.78E-­‐05	  
RAC2,PIK3CA,JAK1,MAPK1,PPP2R2A,MAP3K5	  (includes	  
EG:4217),MAPK13,RHOH,IKBKB,IKBKG,MAP3K7,CYBA,CYBB,CHUK,
PPP1CA,STAT1,MAP2K1,PIK3C2B,MAP3K14,CREBBP,MAP3K1,RAC
1,MAPK9,NCF4,RAP1A,PPP2CB,RHOQ,PPP2R4,CAT,PIK3CB,MAP3K
8,IRF8,PPP2R5E,PPP2R1B,FNBP1	  
Renal	  Cell	  
Carcinoma	  
Signaling	   1.78E-­‐05	  
ETS1,PIK3C2B,UBB,RAC2,PIK3CA,MAPK1,GRB2,CREBBP,SOS2,RAC1
,HIF1A,RAP1A,EP300,PAK1,PTPN11,CUL2,SOS1,PIK3CB,FH,MAP2K
1,TCEB1	  
HGF	  Signaling	  
1.95E-­‐05	  
RAC2,PIK3CA,MAPK1,SOS2,MAP3K5	  (includes	  
EG:4217),PTK2,PAK1,MAP3K7,SOS1,MAP2K1,ETS1,PIK3C2B,MAP3
K14,GRB2,MAP3K1,RAC1,MAPK9,RAP1A,ELF1,ELF2,PTPN11,PIK3C
B,MAP3K8,ELK1,ELK3,CDK2	  
Prostate	  
Cancer	  
Signaling	   2.00E-­‐05	  
PIK3C2B,RAC2,PIK3CA,PA2G4,MAPK1,SRD5A1,GRB2,CREBBP,SOS2
,ABL1,RAC1,CASP9,FOXO1,HSP90AB1,SOS1,CREB1,ATF4,HSP90AA
1,PIK3CB,CHUK,GSK3B,MAP2K1,CDK2	  
ERK/MAPK	  
Signaling	  
2.34E-­‐05	  
PRKACB,RAC2,FYN,PIK3CA,MAPK1,PPP2R2A,SOS2,H3F3B,TLN1,EIF
4E,PTK2,BRAF,MYC,YWHAQ	  (includes	  
EG:10971),PAK1,CREB1,SOS1,ATF4,PPP1CA,STAT1,MAP2K1,ETS1,P
IK3C2B,GRB2,PRKAR2A,RAC1,MAPKAPK5,RAP1A,ELF1,PPP2CB,ELF
2,PPP2R4,PIK3CB,RPS6KA5,PPP2R5E,ELK1,PPP2R1B,ELK3	  
Lymphotoxin	  Î²	  
Receptor	  
Signaling	   2.51E-­‐05	  
PIK3C2B,RAC2,MAP3K14,TRAF3,PIK3CA,MAPK1,CREBBP,RAC1,LTB,
EP300,IKBKB,IKBKG,CASP9,CYCS	  (includes	  
EG:54205),PIK3CB,IKBKAP,CHUK,TRAF5	  
PKCÎ¸	  Signaling	  
in	  T	  
Lymphocytes	  
2.82E-­‐05	  
RAC2,FYN,PIK3CA,HLA-­‐DOA,MAPK1,NFATC3,SOS2,HLA-­‐
DMB,MAP3K5	  (includes	  
EG:4217),IKBKB,IKBKG,MAP3K7,SOS1,CHUK,MAP3K14,PIK3C2B,GR
B2,MAP3K1,RAC1,NFATC1,PPP3CC,HLA-­‐DQB1,POU2F1,CD80,HLA-­‐
DOB,MAP3K8,PIK3CB,VAV1	  
Aminoacyl-­‐
tRNA	  
Biosynthesis	   3.09E-­‐05	  
CARS,GARS,LARS2,HARS,TARS,MARS,EPRS,NARS,WARS,YARS,KARS
,DARS,AARS,SARS,IARS	  
Insulin	  
Receptor	  
Signaling	  
6.46E-­‐05	  
PRKACB,TSC1,RAC2,FYN,PIK3CA,EIF2B4,JAK1,MAPK1,TRIP10,SGK1,
SOS2,EIF2B2,EIF4E,GYS1,SOS1,GSK3B,PPP1CA,MAP2K1,PIK3C2B,G
RB2,RAC1,PRKAR2A,ACLY,INPP5D,RHOQ,PTPN11,FOXO1,IRS1,SH2
B2,PIK3CB	  
Integrin	  
Signaling	  
6.46E-­‐05	  
RAC2,FYN,PIK3CA,RALA,MAPK1,ARHGEF7,ACTA2,SOS2,ABL1,TLN1,
RHOH,PTK2,BRAF,ITGAE,TSPAN3,PAK1,ARF4,SOS1,ITGAV,ARPC3,G
SK3B,PPP1CA,MAP2K1,PIK3C2B,GRB2,RAC1,BCAR3,ITGAL,RAP1A,I
TGB2,WIPF1,ARF1,RHOQ,CAPNS1,ARF3,WAS,PIK3CB,CAPN7,FNBP
1	  
Death	  
Receptor	  
Signaling	   6.46E-­‐05	  
MAP3K14,TNFRSF10B,TNFSF10,MAP3K5	  (includes	  
EG:4217),XIAP,FAS,DAXX,IKBKB,IKBKG,CASP9,RIPK1,CASP2,CYCS	  
(includes	  EG:54205),CHUK,CFLAR,CASP8,BIRC3,CASP7	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NRF2-­‐
mediated	  
Oxidative	  
Stress	  
Response	   6.76E-­‐05	  
USP14,FTL,PIK3CA,MAPK1,PPIB,ACTA2,DNAJC3,MAP3K5	  (includes	  
EG:4217),DNAJA1,CLPP,EP300,AKR1A1,DNAJC4,MAP3K7,ATF4,JUN
D,DNAJA2,GCLM,TXN,GSK3B,MAP2K1,DNAJC16,NFE2L2,PIK3C2B,
UBB,MAP3K1,CREBBP,MAPK9,DNAJC11,GSR,STIP1,CAT,CCT7,PIK3
CB,DNAJB6,FTH1	  
EGF	  Signaling	  
7.24E-­‐05	  
PIK3C2B,PIK3CA,JAK1,MAPK1,GRB2,SOS2,MAP3K1,ITPR1,ITPR3,SO
S1,CSNK2A1,PIK3CB,STAT1,ELK1,MAP2K1	  
RANK	  Signaling	  
in	  Osteoclasts	  
7.94E-­‐05	  
PIK3C2B,MAP3K14,RAC2,PIK3CA,MAPK1,MAP3K1,RAC1,MAPK9,N
FATC1,MAP3K5	  (includes	  
EG:4217),PPP3CC,MAPK13,XIAP,IKBKB,IKBKG,MAP3K7,PIK3CB,MA
P3K8,CHUK,TRAF5,ELK1,MAP2K1,BIRC3	  
Small	  Cell	  Lung	  
Cancer	  
Signaling	   8.91E-­‐05	  
PIK3C2B,RAC2,TRAF3,PIK3CA,PA2G4,ABL1,RAC1,SKP2,MYC,PTK2,I
KBKB,IKBKG,CASP9,CDK4,CYCS	  (includes	  
EG:54205),PIK3CB,CHUK,TRAF5,RXRB,CDK2	  
CD40	  Signaling	  
9.12E-­‐05	  
PIK3C2B,MAP3K14,TRAF3,PIK3CA,ICAM1,MAPK1,TNFAIP3,MAPK9,
MAPK13,IKBKB,IKBKG,CD40,MAP3K7,PIK3CB,IKBKAP,CHUK,TRAF5,
MAP2K1	  
GM-­‐CSF	  
Signaling	   1.48E-­‐04	  
ETS1,PIK3C2B,RAC2,PIK3CA,MAPK1,GRB2,SOS2,RAC1,PPP3CC,CSF
2RB,PTPN11,PIM1,SOS1,LYN,PIK3CB,STAT1,ELK1,MAP2K1	  
IL-­‐4	  Signaling	  
1.48E-­‐04	  
PIK3C2B,RAC2,HLA-­‐
DOA,IL4R,PIK3CA,JAK1,IRF4,GRB2,NFATC3,SOS2,RAC1,HLA-­‐
DMB,NFATC1,INPP5D,HLA-­‐DQB1,IRS1,SOS1,HLA-­‐DOB,PIK3CB	  
Endoplasmic	  
Reticulum	  
Stress	  Pathway	   1.48E-­‐04	  
CASP9,XBP1,DNAJC3,ATF4,MAP3K5	  (includes	  
EG:4217),EIF2S1,HSPA5,CASP7,MBTPS2	  
FAK	  Signaling	  
1.48E-­‐04	  
PIK3C2B,FYN,RAC2,PIK3CA,MAPK1,GRB2,ARHGEF7,CSK,ACTA2,SO
S2,RAC1,TLN1,GIT2,PTK2,PAK1,CAPNS1,WAS,ARHGEF6,SOS1,PIK3
CB,CAPN7,MAP2K1	  
TNFR1	  
Signaling	   1.95E-­‐04	  
MAP3K14,MAP3K1,TNFAIP3,XIAP,IKBKB,PAK1,IKBKG,CASP9,RIPK1,
CASP2,CYCS	  (includes	  EG:54205),CHUK,CASP8,BIRC3,CASP7	  
Chronic	  
Myeloid	  
Leukemia	  
Signaling	   2.00E-­‐04	  
PIK3C2B,RAC2,PIK3CA,RBL2,PA2G4,MAPK1,HDAC2,GRB2,SOS2,AB
L1,RAC1,HDAC9	  (includes	  
EG:9734),E2F3,MYC,IKBKB,IKBKG,PTPN11,CDK4,SOS1,E2F5,PIK3CB
,CHUK,MAP2K1	  
T	  Cell	  Receptor	  
Signaling	  
2.29E-­‐04	  
PIK3C2B,FYN,PTPN7,PIK3CA,MAPK1,GRB2,NFATC3,CSK,MAP3K1,S
OS2,RAC1,NFATC1,PPP3CC,PTPRC,BTK,IKBKB,IKBKG,SOS1,VAV1,PI
K3CB,CHUK,ELK1,MAP2K1	  
p70S6K	  
Signaling	  
2.29E-­‐04	  
RAC2,PIK3CA,JAK1,MAPK1,PPP2R2A,SOS2,CD79A,YWHAQ	  
(includes	  
EG:10971),SOS1,MAP2K1,PIK3C2B,IL4R,CD19,CD79B,GRB2,RAC1,P
LCL2,GNAI2,BTK,PPP2CB,PPP2R4,IRS1,SYK,LYN,PIK3CB,PPP2R5E,P
PP2R1B	  
TWEAK	  
Signaling	   2.69E-­‐04	  
IKBKB,MAP3K14,TRAF3,IKBKG,RIPK1,CASP9,CYCS	  (includes	  
EG:54205),CHUK,CASP8,BIRC3,CASP7,XIAP	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FLT3	  Signaling	  
in	  
Hematopoietic	  
Progenitor	  
Cells	   2.95E-­‐04	  
PIK3C2B,RAC2,PIK3CA,MAPK1,GRB2,SOS2,RAC1,MAPK13,EIF4E,IN
PP5D,PTPN11,CREB1,SOS1,ATF4,PIK3CB,RPS6KA5,STAT1,ELK1,MA
P2K1	  
Hereditary	  
Breast	  Cancer	  
Signaling	  
3.24E-­‐04	  
RAC2,PIK3CA,POLR2D,HDAC9	  (includes	  
EG:9734),MRE11A,DDB2,RAD50,EP300,CHEK1,POLR2H,ATM,PIK3C
2B,UBB,HDAC2,FANCG,TUBG1,CREBBP,RAC1,RFC5,FANCL,RFC4,PO
LR2E,CDK4,PIK3CB,POLR2I,RFC3	  
4-­‐1BB	  Signaling	  
in	  T	  
Lymphocytes	   3.31E-­‐04	  
IKBKB,MAP3K14,IKBKG,MAPK1,TNFSF9,MAP3K1,MAPK9,IKBKAP,C
HUK,MAP3K5	  (includes	  EG:4217),MAP2K1	  
B	  Cell	  
Activating	  
Factor	  
Signaling	   3.31E-­‐04	  
MAP3K14,TRAF3,NFATC3,MAP3K1,MAPK9,NFATC1,MAPK13,IKBK
B,IKBKG,IKBKAP,TRAF5,CHUK,ELK1	  
Cell	  Cycle:	  
G1/S	  
Checkpoint	  
Regulation	   3.89E-­‐04	  
RBL2,PA2G4,HDAC2,ABL1,HDAC9	  (includes	  
EG:9734),E2F3,SKP1,SKP2,MYC,CCND3,CDK4,E2F5,BTRC,GSK3B,CD
K2,ATM	  
Pyruvate	  
Metabolism	  
3.89E-­‐04	  
ACSL3,ACAT2,MDH1,LDHB,GLO1,PDHA1	  (includes	  
EG:5160),HADHB,AKR1A1,PCK2,BCKDHA,DLAT,PDHX,ACAT1,DLD,
ME2,MDH2,HADHA,LDHA,ACSL1,ACYP2	  (includes	  EG:98)	  
iCOS-­‐iCOSL	  
Signaling	  in	  T	  
Helper	  Cells	  
4.07E-­‐04	  
PIK3C2B,RAC2,HLA-­‐DOA,PIK3CA,GRB2,NFATC3,CSK,RAC1,HLA-­‐
DMB,NFATC1,ITPR1,PPP3CC,INPP5D,HLA-­‐
DQB1,PTPRC,IKBKB,IKBKG,CD80,CD40,ITPR3,HLA-­‐
DOB,VAV1,PIK3CB,CHUK	  
CD27	  Signaling	  
in	  
Lymphocytes	   4.17E-­‐04	  
MAP3K14,MAP3K1,MAPK9,MAP3K5	  (includes	  
EG:4217),IKBKB,IKBKG,CASP9,MAP3K7,CYCS	  (includes	  
EG:54205),IKBKAP,MAP3K8,TRAF5,CHUK,CASP8,MAP2K1	  
Phospholipase	  
C	  Signaling	  
4.17E-­‐04	  
PEBP1,FYN,RALA,MAPK1,NFATC3,ARHGEF7,SOS2,GNB5,HDAC9	  
(includes	  
EG:9734),RHOH,CD79A,GNG7,EP300,CREB1,SOS1,ATF4,ARHGEF2,
MARCKS,GNA13,PPP1CA,MAP2K1,CD79B,HDAC2,GRB2,ADCY3,CR
EBBP,RAC1,NFATC1,PPP3CC,ITPR1,GNG5,RAP1A,BTK,RHOQ,SYK,A
RHGEF6,ITPR3,LYN,ARHGEF18,MEF2C,FNBP1	  
Endometrial	  
Cancer	  
Signaling	   5.25E-­‐04	  
RAC2,PIK3C2B,PIK3CA,MAPK1,GRB2,SOS2,RAC1,CTNNA1,MYC,CAS
P9,SOS1,PIK3CB,GSK3B,ELK1,MAP2K1	  
GNRH	  Signaling	  
5.50E-­‐04	  
PRKACB,MAPK1,GNA11,SOS2,MAPK13,MAP3K5	  (includes	  
EG:4217),PTK2,PAK1,MAP3K7,SOS1,CREB1,ATF4,MAP2K1,MAP3K
14,GRB2,CREBBP,MAP3K1,ADCY3,RAC1,PRKAR2A,MAPK9,ITPR1,G
NAI2,ITPR3,MAP3K8,ELK1	  
B	  Cell	  
Development	   5.50E-­‐04	  
HLA-­‐DQB1,PTPRC,CD19,HLA-­‐DOA,SPN,CD79B,CD80,CD40,HLA-­‐
DOB,HLA-­‐DMB,IL7,CD79A	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Estrogen	  
Receptor	  
Signaling	  
5.75E-­‐04	  
TAF12	  (includes	  
EG:6883),POLR2D,MAPK1,GRB2,CDK7,CREBBP,SOS2,PHB2,H3F3B,
TAF7,NCOA3,EP300,KAT2B,DDX5,PCK2,TAF5,POLR2E,SOS1,POLR2
H,NCOR2,NRIP1,POLR2I,MAP2K1,CARM1	  
IL-­‐2	  Signaling	  
6.17E-­‐04	  
RAC2,PIK3C2B,PIK3CA,JAK1,MAPK1,GRB2,SOS2,RAC1,PTPN11,SYK,
SOS1,CSNK2A1,PIK3CB,ELK1,MAP2K1	  
mTOR	  
Signaling	  
6.17E-­‐04	  
TSC1,RAC2,PIK3CA,MAPK1,PPP2R2A,FKBP1A,HIF1A,EIF4G1,RHOH,
EIF4E,EIF3B,RHEB,PIK3C2B,MAPKAP1,VEGFB	  (includes	  
EG:7423),RAC1,EIF3J,PPP2CB,RHOQ,EIF3C,PPP2R4,IRS1,EIF4A1,RP
S6KA5,PIK3CB,PPP2R5E,PPP2R1B,FNBP1	  
Angiopoietin	  
Signaling	   6.17E-­‐04	  
PIK3C2B,RAC2,PIK3CA,GRB2,RAC1,PTK2,IKBKB,PAK1,TNIP1,IKBKG,
CASP9,FOXO1,PTPN11,SOS1,PIK3CB,IKBKAP,CHUK	  
Non-­‐Small	  Cell	  
Lung	  Cancer	  
Signaling	   6.17E-­‐04	  
RAC2,PIK3C2B,PIK3CA,PA2G4,MAPK1,GRB2,SOS2,ABL1,RAC1,ITPR
1,CASP9,CDK4,SOS1,ITPR3,PIK3CB,RXRB,MAP2K1	  
Apoptosis	  
Signaling	  
6.46E-­‐04	  
MAP3K14,MAPK1,BAX,MAP3K5	  (includes	  
EG:4217),DFFA,XIAP,FAS,IKBKB,IKBKG,CAPNS1,CASP9,CASP2,CYCS	  
(includes	  
EG:54205),CHUK,CAPN7,CASP8,MAP2K1,BIRC3,CASP7,AIFM1	  
April	  Mediated	  
Signaling	   6.61E-­‐04	  
IKBKB,MAP3K14,TRAF3,IKBKG,NFATC3,MAP3K1,MAPK9,NFATC1,
MAPK13,TRAF5,CHUK,ELK1	  
SAPK/JNK	  
Signaling	  
6.76E-­‐04	  
PIK3C2B,RAC2,PIK3CA,GRB2,NFATC3,SOS2,MAP3K1,RAC1,MAPK9,
NFATC1,MAP3K5	  (includes	  
EG:4217),GNG5,GNG7,DAXX,RIPK1,MAP3K7,IRS1,SOS1,PIK3CB,GN
A13,ELK1	  
NF-­‐ÎºB	  
Activation	  by	  
Viruses	   6.76E-­‐04	  
PIK3C2B,RAC2,MAP3K14,PIK3CA,MAPK1,MAP3K1,RAC1,ITGAL,ITG
B2,IKBKB,IKBKG,RIPK1,ITGAV,PIK3CB,IKBKAP,CHUK,EIF2AK2,CR2	  
VEGF	  Signaling	  
7.08E-­‐04	  
EIF2S2,PIK3C2B,RAC2,PIK3CA,EIF2B4,VEGFB	  (includes	  
EG:7423),MAPK1,GRB2,ACTA2,SOS2,RAC1,HIF1A,EIF2S1,EIF2B2,PT
K2,FOXO1,EIF1AX,SOS1,PIK3CB,MAP2K1	  
Breast	  Cancer	  
Regulation	  by	  
Stathmin1	  
7.59E-­‐04	  
PRKACB,PIK3CA,MAPK1,PPP2R2A,ARHGEF7,SOS2,GNB5,E2F3,GNG
7,PAK1,SOS1,E2F5,ARHGEF2,GNA13,PPP1CA,MAP2K1,PIK3C2B,GR
B2,TUBG1,ADCY3,RAC1,PRKAR2A,ITPR1,GNG5,GNAI2,PPP2CB,PPP
2R4,ARHGEF6,ITPR3,PIK3CB,ARHGEF18,PPP2R5E,PPP2R1B,CDK2	  
CTLA4	  
Signaling	  in	  
Cytotoxic	  T	  
Lymphocytes	   7.59E-­‐04	  
PIK3C2B,FYN,RAC2,HLA-­‐DOA,PIK3CA,PPP2R2A,GRB2,RAC1,HLA-­‐
DMB,AP2S1,HLA-­‐
DQB1,PPP2CB,AP1G2,CD80,PTPN11,PPP2R4,SYK,HLA-­‐
DOB,PIK3CB,PPP2R5E,PPP2R1B	  
FcÎ³RIIB	  
Signaling	  in	  B	  
Lymphocytes	   7.94E-­‐04	  
BTK,PIK3C2B,PIK3CA,CD79B,GRB2,SYK,SOS1,LYN,MAPK9,PIK3CB,I
NPP5D,CD79A	  
Glutamate	  
Metabolism	   7.94E-­‐04	  
GSR,GFPT1,GMPS,GLS,GLUD1,GOT1,CAD,GCLM,GOT2,PPAT,GLUD
2,EPRS	  
Myc	  Mediated	  
Apoptosis	   7.94E-­‐04	  
PIK3C2B,RAC2,PIK3CA,GRB2,SOS2,RAC1,MAPK9,BAX,FAS,MYC,YW
HAQ	  (includes	  EG:10971),CASP9,SOS1,CYCS	  (includes	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Signaling	   EG:54205),PIK3CB,CASP8	  
Role	  of	  CHK	  
Proteins	  in	  Cell	  
Cycle	  
Checkpoint	  
Control	   8.13E-­‐04	  
RFC4,TLK1,E2F5,MRE11A,RFC5,E2F3,RAD50,CDK2,CHEK1,ATM,RFC
3	  
Regulation	  of	  
IL-­‐2	  Expression	  
in	  Activated	  
and	  Anergic	  T	  
Lymphocytes	   8.13E-­‐04	  
SMAD2,FYN,MAPK1,GRB2,NFATC3,MAP3K1,SOS2,RAC1,MAPK9,N
FATC1,PPP3CC,IKBKB,IKBKG,CD80,SOS1,VAV1,CHUK,ELK1,MAP2K1	  
Alanine	  and	  
Aspartate	  
Metabolism	   8.51E-­‐04	  
ASNS,PDHA1	  (includes	  
EG:5160),ADSL,NARS,DLAT,PDHX,DLD,KARS,DARS,GOT1,CAD,AARS
,GOT2	  
PDGF	  Signaling	  
8.91E-­‐04	  
PIK3C2B,PIK3CA,JAK1,MAPK1,GRB2,SOS2,MAP3K1,ABL1,INPP5D,
MYC,SOS1,CSNK2A1,PIK3CB,EIF2AK2,STAT1,ELK1,MAP2K1	  
Role	  of	  BRCA1	  
in	  DNA	  
Damage	  
Response	   9.12E-­‐04	  
RBL2,FANCG,RBBP8,MRE11A,RFC5,E2F3,FANCL,RAD50,CHEK1,PO
U2F1,RFC4,E2F5,STAT1,RFC3,ATM	  
Inositol	  
Phosphate	  
Metabolism	  
1.00E-­‐03	  
MINPP1,PIK3CA,MAPK1,SGK1,MTMR1,BRAF,PAK1,CDK8,PIM1,PRP
F4B,MAP2K1,PMPCA,ATM,PIK3C2B,IMPA1,CDK7,MAPK6,MAPK9,P
LCL2,INPP5D,INPP5F,CDK4,MAP3K8,PIK3CB,EIF2AK2,CDK2,DYRK1
A	  
LPS-­‐stimulated	  
MAPK	  Signaling	  
1.00E-­‐03	  
PIK3C2B,MAP3K14,PIK3CA,MAPK1,RAC1,MAPK9,MAPK13,MAP3K
5	  (includes	  
EG:4217),IKBKB,PAK1,IKBKG,MAP3K7,CREB1,PIK3CB,CHUK,ELK1,M
AP2K1	  
IL-­‐3	  Signaling	  
1.00E-­‐03	  
PIK3C2B,RAC2,PIK3CA,JAK1,MAPK1,GRB2,RAC1,PPP3CC,INPP5D,C
SF2RB,PAK1,FOXO1,SOS1,PIK3CB,STAT1,ELK1,MAP2K1	  
Valine,	  Leucine	  
and	  Isoleucine	  
Degradation	   1.00E-­‐03	  
ECHS1,ACAT2,PCCB,GCDH,BCAT1,HIBCH,HADHB,BCAT2,BCKDHA,A
CAT1,OXCT1,HMGCS1,ACADM,HADHA,ALDH6A1,HADH,MCCC2	  
CREB	  Signaling	  
in	  Neurons	  
1.10E-­‐03	  
PRKACB,RAC2,PIK3CA,POLR2D,MAPK1,SOS2,GNA11,GNB5,GNG7,E
P300,SOS1,CREB1,POLR2H,ATF4,GNA13,MAP2K1,PIK3C2B,GRB2,C
REBBP,ADCY3,RAC1,PRKAR2A,PLCL2,ITPR1,GNG5,GNAI2,POLR2E,I
TPR3,PIK3CB,ELK1,POLR2I	  
Role	  of	  PKR	  in	  
Interferon	  
Induction	  and	  
Antiviral	  
Response	   1.15E-­‐03	  
IKBKB,TRAF3,IKBKG,CASP9,MAP3K7,CYCS	  (includes	  
EG:54205),TRAF5,CHUK,EIF2AK2,STAT1,CASP8,EIF2S1	  
Pancreatic	  
Adenocarcino
ma	  Signaling	   1.20E-­‐03	  
PIK3C2B,SMAD2,RAC2,PIK3CA,RALA,JAK1,VEGFB	  (includes	  
EG:7423),PA2G4,MAPK1,GRB2,ABL1,RAC1,MAPK9,E2F3,CASP9,CD
K4,E2F5,PIK3CB,STAT1,ELK1,MAP2K1,CDK2	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AMPK	  Signaling	  
1.20E-­‐03	  
PRKACB,TSC1,RAC2,PIK3CA,PPP2R2A,MAPK13,PPM1D,GYS1,FASN,
PPM1A,PIK3C2B,PFKFB3,RAC1,PRKAR2A,PFKP,PFKM,PPP2CB,KAT2
B,PPP2R4,IRS1,PIK3CB,PPP2R5E,HMGCR,AK2,PPP2R1B,PPAT	  
Cell	  Cycle	  
Regulation	  by	  
BTG	  Family	  
Proteins	   1.26E-­‐03	  
PPP2CB,PRMT1,PPP2R4,PPP2R2A,CDK4,BTG2,E2F5,PPP2R5E,E2F3,
PPP2R1B,CDK2	  
Cardiac	  
Hypertrophy	  
Signaling	  
1.29E-­‐03	  
PRKACB,PIK3CA,EIF2B4,MAPK1,GNA11,GNB5,MAP3K5	  (includes	  
EG:4217),MAPK13,RHOH,EIF2B2,GNG7,EIF4E,EP300,MAP3K7,CRE
B1,SOS1,GSK3B,GNA13,MAP2K1,PIK3C2B,MAP3K14,GRB2,CREBBP
,ADCY3,MAP3K1,PRKAR2A,MAPK9,PPP3CC,PLCL2,GNG5,GNAI2,RH
OQ,IRS1,PIK3CB,MAP3K8,MEF2C,ELK1,FNBP1	  
IGF-­‐1	  Signaling	  
1.66E-­‐03	  
PRKACB,PIK3C2B,RAC2,PIK3CA,MAPK1,GRB2,SOS2,PRKAR2A,RAC1
,YWHAQ	  (includes	  
EG:10971),PTK2,CASP9,FOXO1,PTPN11,IRS1,SOS1,CSNK2A1,PIK3C
B,ELK1,MAP2K1	  
Propanoate	  
Metabolism	   1.70E-­‐03	  
ACSL3,ECHS1,ACAT2,PCCB,GCDH,LDHB,HIBCH,HADHB,SUCLA2,DH
CR24,ACAT1,ACADM,HADHA,LDHA,ACSL1,ALDH6A1	  
Synthesis	  and	  
Degradation	  of	  
Ketone	  Bodies	   1.74E-­‐03	   HADHB,ACAT2,ACAT1,OXCT1,HMGCS1,HADHA	  
Type	  I	  Diabetes	  
Mellitus	  
Signaling	  
1.91E-­‐03	  
MAP3K14,HLA-­‐DOA,JAK1,PIAS1,MAPK9,HLA-­‐DMB,HSPD1,MAP3K5	  
(includes	  EG:4217),MAPK13,FAS,HLA-­‐
DQB1,IKBKB,IKBKG,RIPK1,CASP9,CD80,MAP3K7,HLA-­‐DOB,CYCS	  
(includes	  EG:54205),CHUK,CASP8,STAT1	  
JAK/Stat	  
Signaling	   2.04E-­‐03	  
PIK3C2B,RAC2,PIK3CA,JAK1,PIAS2,MAPK1,GRB2,SOS2,PIAS1,RAC1,
PTPN11,SOS1,PIK3CB,STAT1,MAP2K1	  
Melanocyte	  
Development	  
and	  
Pigmentation	  
Signaling	   2.24E-­‐03	  
PRKACB,PIK3C2B,PIK3CA,MAPK1,GRB2,CREBBP,ADCY3,SOS2,PRKA
R2A,EP300,PTPN11,SH2B2,CREB1,SOS1,ATF4,PIK3CB,RPS6KA5,MA
P2K1	  
FGF	  Signaling	  
2.57E-­‐03	  
PIK3C2B,RAC2,PIK3CA,MAPK1,GRB2,SOS2,MAP3K1,RAC1,ITPR1,M
APK13,MAP3K5	  (includes	  
EG:4217),PTPN11,SOS1,CREB1,ATF4,PIK3CB,RPS6KA5,MAP2K1	  
Renin-­‐
Angiotensin	  
Signaling	   2.75E-­‐03	  
PRKACB,PIK3C2B,PIK3CA,MAPK1,GRB2,ADCY3,SOS2,MAP3K1,PRK
AR2A,RAC1,MAPK9,ITPR1,MAPK13,PTK2,PAK1,SOS1,ITPR3,PIK3CB
,STAT1,ELK1,MAP2K1	  
Valine,	  Leucine	  
and	  Isoleucine	  
Biosynthesis	   2.75E-­‐03	   PDHA1	  (includes	  EG:5160),BCAT1,BCAT2,LARS2,IARS,ILVBL	  
Leukocyte	  
Extravasation	  
Signaling	  
2.95E-­‐03	  
RAC2,PIK3CA,SPN,ICAM1,ACTA2,CTNNA1,ABL1,MAPK13,RHOH,PT
K2,EZR,CYBA,SIPA1,CYBB,PIK3C2B,CXCR4,ARHGAP4,RAC1,MAPK9,
NCF4,RAP1A,ITGAL,BTK,GNAI2,ITGB2,WIPF1,PTPN11,WAS,PECAM
1,PIK3CB,VAV1,CTNND1	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p53	  Signaling	  
2.95E-­‐03	  
PIK3C2B,RAC2,PIK3CA,TNFRSF10B,RAC1,BAX,FAS,CHEK1,EP300,CC
NG1,SCO2	  (includes	  
EG:9997),KAT2B,CDK4,PIK3CB,GSK3B,HIPK2,PMAIP1,CDK2,ATM	  
Pyrimidine	  
Metabolism	  
3.02E-­‐03	  
ENTPD4,POLR2D,DKC1,NME2,POLD4,POLB,POLR1C,POLD3,POLR3
G,POLR2H,TXN,POLR3C,TYMS,RP2,DCK,POLE2,PRIM2,RRM2,RFC5,
POLD1,UMPS,CTPS,RRM1	  (includes	  
EG:6240),POLR2E,POLA2,CAD,POLR2I,RFC3	  
PPARÎ±/RXRÎ±	  
Activation	  
3.09E-­‐03	  
PRKACB,MAPK1,SOS2,GNA11,EP300,IKBKB,IKBKG,HSP90AB1,MAP
3K7,FASN,SOS1,CHUK,GOT2,MAP2K1,SMAD2,MAP3K14,GRB2,AC
OX1,CREBBP,ADCY3,PRKAR2A,PLCL2,NCOA3,AIP,CAND1,IRS1,HSP9
0AA1,NCOR2,ADIPOR2	  
One	  Carbon	  
Pool	  by	  Folate	   3.31E-­‐03	   TYMS,GCSH,MTHFD2,MTR,MTHFD1,ATIC,SHMT2,GART	  
Glycolysis/Gluc
oneogenesis	  
3.31E-­‐03	  
PGK1,ACSL3,PGM1,TPI1,PFKP,LDHB,PFKM,PDHA1	  (includes	  
EG:5160),AKR1A1,GPI,ENO1,DLAT,PGAM1,PDHX,DLD,ALDOA,LDH
A,ACSL1,ACYP2	  (includes	  EG:98),ALDOC	  
Role	  of	  NFAT	  in	  
Cardiac	  
Hypertrophy	  
3.55E-­‐03	  
PRKACB,RAC2,PIK3CA,MAPK1,SOS2,GNB5,HDAC9	  (includes	  
EG:9734),MAPK13,GNG7,EP300,CABIN1,MAP3K7,SOS1,GSK3B,MA
P2K1,PIK3C2B,HDAC2,GRB2,ADCY3,MAP3K1,RAC1,PRKAR2A,MAP
K9,PPP3CC,ITPR1,PLCL2,GNG5,GNAI2,ITPR3,PIK3CB,MEF2C	  
RAR	  Activation	  
3.63E-­‐03	  
PRKACB,RAC2,PIK3CA,TRIM24,MAP3K5	  (includes	  
EG:4217),MAPK13,EP300,PRMT1,PNRC1,CSNK2A1,RXRB,MAP2K1,
SMAD2,PRMT2,RDH11,CSK,CDK7,CREBBP,ADCY3,MAP3K1,RAC1,P
RKAR2A,MAPK9,KAT2B,CSF2RB,PIK3CB,NRIP1,NCOR2,CARM1	  
IL-­‐8	  Signaling	  
3.98E-­‐03	  
RAC2,PIK3CA,ICAM1,MAPK1,GNB5,RHOH,GNG7,PTK2,BRAF,IKBKB,
IKBKG,CYBB,CHUK,GNA13,MAP2K1,CR2,PIK3C2B,VEGFB	  (includes	  
EG:7423),RAC1,MAPK9,BAX,GNG5,CSTB,GNAI2,ITGB2,CCND3,RHO
Q,PIK3CB,FNBP1	  
Glioblastoma	  
Multiforme	  
Signaling	   4.68E-­‐03	  
TSC1,RAC2,PIK3CA,MAPK1,SOS2,E2F3,RHOH,MYC,SOS1,E2F5,GSK
3B,MAP2K1,PIK3C2B,GRB2,RAC1,PLCL2,ITPR1,TCF3,APC,RHOQ,FO
XO1,CDK4,ITPR3,PIK3CB,CDK2,FNBP1	  
NF-­‐ÎºB	  
Signaling	  
4.68E-­‐03	  
PRKACB,RAC2,TLR1,IL1A,TRAF3,PIK3CA,TNFAIP3,EP300,IKBKB,IKBK
G,MAP3K7,CSNK2A1,CHUK,TRAF5,GSK3B,MAP3K14,PIK3C2B,HDA
C2,CREBBP,RAC1,RIPK1,CD40,BTRC,PIK3CB,MAP3K8,EIF2AK2	  
PPAR	  Signaling	  
4.68E-­‐03	  
MAP3K14,IL1A,MAPK1,GRB2,CREBBP,SOS2,AIP,EP300,IKBKB,IKBK
G,HSP90AB1,MAP3K7,SOS1,HSP90AA1,CHUK,NCOR2,NRIP1,MAP2
K1	  
Fc	  Epsilon	  RI	  
Signaling	   5.25E-­‐03	  
PIK3C2B,FYN,RAC2,PIK3CA,MAPK1,GRB2,SOS2,RAC1,MAPK9,MAP
K13,INPP5D,BTK,PTPN11,SYK,SOS1,LYN,VAV1,PIK3CB,MAP2K1	  
Prolactin	  
Signaling	   5.62E-­‐03	  
FYN,PIK3C2B,PIK3CA,MAPK1,GRB2,CREBBP,SOS2,EP300,MYC,PTP
N11,IRS1,SOS1,PIK3CB,STAT1,MAP2K1	  
PTEN	  Signaling	  
5.89E-­‐03	  
RAC2,PIK3CA,MAPK1,GRB2,SOS2,RAC1,INPP5D,PTK2,IKBKB,IKBKG,
CASP9,FOXO1,SOS1,CSNK2A1,PIK3CB,CHUK,GSK3B,MAP2K1	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Ephrin	  
Receptor	  
Signaling	  
5.89E-­‐03	  
FYN,RAC2,MAPK1,SOS2,GNA11,GNB5,ABL1,GNG7,GRINA,PTK2,PA
K1,SOS1,CREB1,ARPC3,ATF4,GNA13,MAP2K1,MAP3K14,VEGFB	  
(includes	  
EG:7423),CXCR4,GRB2,RAC1,GNG5,RAP1A,GNAI2,WIPF1,PTPN11,
ABI1,WAS	  
Nur77	  
Signaling	  in	  T	  
Lymphocytes	   6.76E-­‐03	  
HLA-­‐DOA,HDAC2,HDAC9	  (includes	  EG:9734),NFATC1,HLA-­‐
DMB,PPP3CC,CABIN1,EP300,HLA-­‐DQB1,CASP9,CD80,CYCS	  
(includes	  EG:54205),HLA-­‐DOB	  
Cardiac	  Î²-­‐
adrenergic	  
Signaling	   7.24E-­‐03	  
PRKACB,ADRBK1,PPP2R2A,ADRBK2,ADCY3,PRKAR2A,GNB5,ATP2A
3,GNG5,ATP2A2,GNG7,PDE8A,PPP2CB,AKAP13,PPP2R4,AKAP10,P
PP2R5E,PPP1CA,AKAP9,PPP2R1B,PKIG,AKAP1	  
IL-­‐1	  Signaling	  
7.41E-­‐03	  
PRKACB,MAP3K14,IL1A,ADCY3,GNA11,MAP3K1,GNB5,PRKAR2A,M
APK9,MAPK13,GNG5,GNG7,GNAI2,IKBKB,IKBKG,MAP3K7,CHUK,G
NA13	  
Docosahexaen
oic	  Acid	  (DHA)	  
Signaling	   7.76E-­‐03	  
RAC2,PIK3C2B,PIK3CA,CASP9,FOXO1,RAC1,CYCS	  (includes	  
EG:54205),PIK3CB,BAX,GSK3B	  
Dendritic	  Cell	  
Maturation	  
7.76E-­‐03	  
RAC2,HLA-­‐DOA,IL1A,PIK3CA,ICAM1,MAPK1,LTB,HLA-­‐
DMB,CD83,MAPK13,IKBKB,IKBKG,CREB1,ATF4,CHUK,STAT1,MAP3
K14,PIK3C2B,RAC1,MAPK9,CD58,HLA-­‐DQB1,CD40,CD80,HLA-­‐
DOB,PIK3CB,IRF8	  
Amyotrophic	  
Lateral	  
Sclerosis	  
Signaling	   8.13E-­‐03	  
PIK3C2B,PIK3CA,VEGFB	  (includes	  
EG:7423),RAB5A,RAC1,BAX,XIAP,GRINA,CCS,PAK1,CAPNS1,CASP9,
CAT,CYCS	  (includes	  EG:54205),PIK3CB,CAPN7,BIRC3,CASP7	  
ATM	  Signaling	  
8.32E-­‐03	  
MDM4,TLK1,CREB1,ABL1,MAPK9,ATF4,MRE11A,MAPK13,RAD50,C
DK2,CHEK1,ATM	  
Nicotinate	  and	  
Nicotinamide	  
Metabolism	   8.71E-­‐03	  
MAPK1,SGK1,CDK7,MAPK6,MAPK9,BRAF,PAK1,CDK8,NNT,PIM1,C
DK4,PRPF4B,MAP3K8,NAMPT,EIF2AK2,NADK	  (includes	  
EG:65220),MAP2K1,CDK2,DYRK1A	  
Protein	  Kinase	  
A	  Signaling	  
8.91E-­‐03	  
PRKACB,MYH10,MAPK1,NFATC3,GNB5,H3F3B,CDC23	  (includes	  
EG:8697),GNG7,PTK2,YWHAQ	  (includes	  
EG:10971),BRAF,GYS1,PHKB,CREB1,ATF4,GSK3B,GNA13,CHUK,PPP
1CA,MAP2K1,CREBBP,ADCY3,MAP3K1,PRKAR2A,NFATC1,PPP3CC,
PLCL2,ITPR1,TCF3,ANAPC13,GNG5,RAP1A,PDE8A,GNAI2,AKAP13,
ADD3,KDELR2,ITPR3,AKAP10,ANAPC5,ELK1,KDELR1,AKAP9,AKAP1	  
Activation	  of	  
IRF	  by	  
Cytosolic	  
Pattern	  
Recognition	  
Receptors	   8.91E-­‐03	  
TRAF3,PPIB,CREBBP,MAPK9,ADAR,ISG15,IKBKB,IKBKG,RIPK1,CD40
,SIKE1,IKBKAP,CHUK,STAT1	  
ILK	  Signaling	  
1.00E-­‐02	  
RAC2,MYH10,PIK3CA,MAPK1,PPP2R2A,ACTA2,HIF1A,RHOH,PTK2,
MYC,CREB1,ATF4,GSK3B,PIK3C2B,VEGFB	  (includes	  
EG:7423),RAC1,MAPK9,PPP2CB,ITGB2,RHOQ,PPP2R4,IRS1,ARHGE
F6,SH2B2,PIK3CB,RPS6KA5,PPP2R5E,PPP2R1B,FNBP1	  
Fatty	  Acid	   1.02E-­‐02	   ACSL3,FASN,PCCB,MCAT,MCCC2	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Biosynthesis	  
HIF1Î±	  
Signaling	  
1.05E-­‐02	  
PIK3C2B,RAC2,PIK3CA,VEGFB	  (includes	  
EG:7423),MAPK1,CREBBP,MAPK6,RAC1,MAPK9,MAPK13,HIF1A,LD
HB,EP300,CUL2,HSP90AA1,PIK3CB,APEX1,LDHA,TCEB1	  
TNFR2	  
Signaling	   1.07E-­‐02	   IKBKB,MAP3K14,IKBKG,MAP3K1,TNFAIP3,CHUK,BIRC3,XIAP	  
Oxidative	  
Phosphorylatio
n	  
1.29E-­‐02	  
SDHB,NDUFA9	  (includes	  EG:4704),COX10	  (includes	  
EG:1352),COX8A,NDUFS1,NDUFAB1,NDUFS6	  (includes	  
EG:4726),UQCRFS1,NDUFS2,ATP6V1G1,ATP5G3,NDUFS4,SDHA,ND
UFV1,ATP6V0E2,ATP6V1A,NDUFV2,ATP5B,ATP6V1H,NDUFS8,NDU
FA6,UQCRC2,COX5A,CYC1,UQCRC1	  
Toll-­‐like	  
Receptor	  
Signaling	   1.38E-­‐02	  
IKBKB,MAP3K14,TLR1,LY96,IKBKG,MAP3K7,MAP3K1,MAPK13,CHU
K,EIF2AK2,ELK1	  
CXCR4	  
Signaling	  
1.38E-­‐02	  
RAC2,PIK3CA,MAPK1,GNA11,GNB5,RHOH,GNG7,PTK2,PAK1,GNA1
3,MAP2K1,PIK3C2B,CXCR4,ADCY3,RAC1,MAPK9,ITPR1,GNG5,GNAI
2,RHOQ,ITPR3,LYN,PIK3CB,ELK1,FNBP1	  
fMLP	  Signaling	  
in	  Neutrophils	  
1.38E-­‐02	  
PIK3C2B,PIK3CA,MAPK1,NFATC3,GNB5,RAC1,NFATC1,ITPR1,PPP3
CC,GNG5,GNG7,GNAI2,WAS,ITPR3,CYBB,ARPC3,PIK3CB,ELK1,MAP
2K1	  
Sphingosine-­‐1-­‐
phosphate	  
Signaling	   1.38E-­‐02	  
RAC2,PIK3C2B,PIK3CA,MAPK1,ADCY3,RAC1,CASP4,PLCL2,RHOH,PT
K2,GNAI2,CASP9,RHOQ,CASP2,PIK3CB,GNA13,CASP8,FNBP1,CASP
7	  
Nitric	  Oxide	  
Signaling	  in	  the	  
Cardiovascular	  
System	   1.45E-­‐02	  
PRKACB,RAC2,PIK3C2B,PIK3CA,VEGFB	  (includes	  
EG:7423),RAC1,PRKAR2A,SLC7A1,ATP2A3,ITPR1,ATP2A2,HSP90AB
1,ITPR3,HSP90AA1,PIK3CB	  
Type	  II	  
Diabetes	  
Mellitus	  
Signaling	   1.45E-­‐02	  
PIK3C2B,RAC2,MAP3K14,PIK3CA,ACSL3,MAPK1,MAP3K1,RAC1,MA
PK9,MAP3K5	  (includes	  
EG:4217),IKBKB,IKBKG,MAP3K7,IRS1,SH2B2,ACSL4,PIK3CB,CHUK,A
DIPOR2,ACSL1	  
G	  Beta	  Gamma	  
Signaling	   1.51E-­‐02	  
PRKACB,RAC2,MAPK1,GRB2,GNA11,SOS2,GNB5,RAC1,PRKAR2A,G
NG5,GNG7,GNAI2,BTK,PAK1,SOS1,ARHGEF6,GNA13	  
CNTF	  Signaling	  
1.55E-­‐02	  
PIK3C2B,PIK3CA,JAK1,PTPN11,MAPK1,GRB2,SOS1,PIK3CB,RPS6KA
5,STAT1,MAP2K1	  
Acute	  Myeloid	  
Leukemia	  
Signaling	   1.58E-­‐02	  
RAC2,PIK3C2B,PIK3CA,MAPK1,GRB2,SOS2,RAC1,TCF3,MYC,BRAF,C
SF2RB,PIM1,SOS1,PIK3CB,MAP2K1	  
HMGB1	  
Signaling	   1.66E-­‐02	  
PIK3C2B,RAC2,PIK3CA,IL1A,ICAM1,MAPK1,RAC1,MAPK9,MAPK13,
RHOH,KAT2B,RHOQ,MYST3,PIK3CB,ELK1,MAP2K1,FNBP1	  
Aldosterone	  
Signaling	  in	  
Epithelial	  Cells	   1.78E-­‐02	  
PIK3C2B,ICMT,PIK3CA,MAPK1,SGK1,SOS2,PLCL2,ITPR1,HSPA5,ITPR
3,SOS1,HSP90AA1,PIK3CB,MAP2K1,AHCY	  
TR/RXR	  
Activation	   1.86E-­‐02	  
PIK3C2B,RAC2,PIK3CA,UCP2,GPS2,RAC1,BCL3,PFKP,HIF1A,NCOA3,
EP300,ENO1,FASN,PIK3CB,NCOR2,RXRB	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Thrombin	  
Signaling	  
1.86E-­‐02	  
RAC2,PIK3CA,MAPK1,GNA11,GNB5,MAPK13,RHOH,GNG7,PTK2,IK
BKB,SOS1,CREB1,ARHGEF2,GNA13,MAP2K1,PIK3C2B,GRB2,ADCY3
,RAC1,PLCL2,ITPR1,GNG5,GNAI2,RHOQ,ARHGEF6,ITPR3,PIK3CB,EL
K1,FNBP1	  
D-­‐glutamine	  
and	  D-­‐
glutamate	  
Metabolism	   1.86E-­‐02	   GLS,GLUD1,GLUD2	  
Methionine	  
Metabolism	   1.86E-­‐02	   SRM,AMD1,AHCYL1,ALAS1,MTR,AHCYL2,MARS,AHCY	  
IL-­‐17	  Signaling	  
2.00E-­‐02	  
RAC2,MAP3K14,PIK3C2B,PIK3CA,JAK1,MAPK1,RAC1,MAPK9,MAPK
13,MAP3K7,PIK3CB,GSK3B,ELK1,MAP2K1	  
Relaxin	  
Signaling	  
2.00E-­‐02	  
PRKACB,PIK3C2B,RAC2,PIK3CA,MAPK1,ADCY3,GNA11,GNB5,RAC1,
PRKAR2A,RAP1A,GNG5,GNG7,GNAI2,PDE8A,BRAF,CREB1,PIK3CB,
GNA13,ELK1,MAP2K1	  
IL-­‐6	  Signaling	  
2.04E-­‐02	  
MAP3K14,IL1A,MAPK1,GRB2,SOS2,MAPK9,MAPK13,IKBKB,IKBKG,
PTPN11,MAP3K7,SOS1,CSNK2A1,CHUK,ELK1,MAP2K1	  
Germ	  Cell-­‐
Sertoli	  Cell	  
Junction	  
Signaling	  
2.04E-­‐02	  
PIK3C2B,RAC2,MAP3K14,PIK3CA,MAPK1,TUBG1,ACTA2,MAP3K1,C
TNNA1,RAC1,MAPK9,MAP3K5	  (includes	  
EG:4217),RHOH,PTK2,PAK1,AGGF1,RHOQ,MAP3K7,PIK3CB,MAP3K
8,MTMR2,MAP2K1,FNBP1,CTNND1	  
Pentose	  
Phosphate	  
Pathway	   2.04E-­‐02	   PRPS2,GPI,PGD,TALDO1,PGM1,ALDOA,PFKP,PFKM,ALDOC	  
IL-­‐12	  Signaling	  
and	  Production	  
in	  
Macrophages	   2.04E-­‐02	  
PIK3C2B,RAC2,PIK3CA,MAPK1,RAC1,MAPK9,MAPK13,EP300,JMJD
6,IKBKB,IKBKG,CD40,PIK3CB,MAP3K8,CHUK,IRF8,REL,STAT1,MAP2
K1	  
Leptin	  
Signaling	  in	  
Obesity	   2.14E-­‐02	  
PRKACB,RAC2,PIK3C2B,PIK3CA,MAPK1,GRB2,ADCY3,RAC1,PRKAR2
A,PLCL2,FOXO1,PTPN11,PIK3CB,MAP2K1	  
Biosynthesis	  of	  
Steroids	   2.14E-­‐02	  
FDPS,SQLE,FDFT1,EBP,COX10	  (includes	  
EG:1352),LSS,HMGCR,SC5DL	  
Cell	  Cycle:	  
G2/M	  DNA	  
Damage	  
Checkpoint	  
Regulation	   2.34E-­‐02	   UBB,KAT2B,CDK7,BTRC,SKP1,SKP2,CHEK1,ATM,EP300	  
Caveolar-­‐
mediated	  
Endocytosis	  
Signaling	   2.34E-­‐02	  
FYN,ARCN1,RAB5A,ACTA2,COPA,ABL1,FLOT1,COPB1,ITGAL,COPB2
,ITGB2,ITGAE,FLOT2,ITGAV	  
Androgen	  
Signaling	  
2.40E-­‐02	  
PRKACB,POLR2D,MAPK1,CDK7,CREBBP,GNA11,GNB5,PRKAR2A,G
NG5,GNG7,EP300,GNAI2,HSPA4,KAT2B,POLR2E,POLR2H,HSP90AA
1,GNA13,POLR2I	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Colorectal	  
Cancer	  
Metastasis	  
Signaling	  
2.45E-­‐02	  
PRKACB,RAC2,TLR1,PIK3CA,JAK1,ADRBK1,MAPK1,SOS2,GNB5,RHO
H,GNG7,BRAF,MYC,CASP9,SOS1,GSK3B,STAT1,MAP2K1,PIK3C2B,S
MAD2,VEGFB	  (includes	  
EG:7423),GRB2,ADRBK2,ADCY3,PRKAR2A,RAC1,MAPK9,BAX,TCF3,
GNG5,APC,RHOQ,PIK3CB,FNBP1	  
HER-­‐2	  Signaling	  
in	  Breast	  
Cancer	   2.63E-­‐02	  
RAC2,PIK3C2B,TSC1,PIK3CA,GRB2,SOS2,RAC1,MAP3K5	  (includes	  
EG:4217),ITGB2,CASP9,FOXO1,SOS1,PIK3CB,GSK3B	  
IL-­‐22	  Signaling	   2.69E-­‐02	   RAC2,JAK1,MAPK1,RAC1,MAPK9,MAPK13,STAT1	  
Hypoxia	  
Signaling	  in	  the	  
Cardiovascular	  
System	   3.02E-­‐02	  
UBB,P4HB,UBE2M,HIF1A,UBE2L6,UBE2D1,EP300,HSP90AB1,CREB
1,HSP90AA1,ATF4,LDHA,ATM	  
Calcium-­‐
induced	  T	  
Lymphocyte	  
Apoptosis	   3.09E-­‐02	  
HLA-­‐DQB1,HLA-­‐DOA,HDAC2,ITPR3,HLA-­‐DOB,ATP2A3,HLA-­‐
DMB,PPP3CC,ITPR1,ATP2A2,CABIN1,EP300	  
Butanoate	  
Metabolism	  
3.09E-­‐02	  
SDHA,PDHA1	  (includes	  
EG:5160),HADHB,SDHB,ECHS1,ACAT2,ACAT1,OXCT1,HMGCS1,HA
DHA,HADH,ILVBL	  
FcÎ³	  Receptor-­‐
mediated	  
Phagocytosis	  in	  
Macrophages	  
and	  Monocytes	   3.09E-­‐02	  
FYN,RAC2,MAPK1,ACTA2,RAC1,TLN1,INPP5D,MYO5A,PAK1,WAS,E
ZR,SYK,LYN,ARPC3,RAB11A,VAV1	  
Granzyme	  B	  
Signaling	   3.09E-­‐02	   CASP9,NUMA1,CYCS	  (includes	  EG:54205),CASP8,DFFA	  
N-­‐Glycan	  
Biosynthesis	   3.09E-­‐02	  
FUT8,B4GALT4,DAD1,RPN2,MAN1A1,DDOST,MAN2A1,DPM2,RPN
1,B4GALT3,STT3A	  
GÎ±12/13	  
Signaling	  
3.16E-­‐02	  
PIK3C2B,RAC2,PIK3CA,MAPK1,MAP3K1,RAC1,MAPK9,MAP3K5	  
(includes	  
EG:4217),BTK,PTK2,IKBKB,IKBKG,PIK3CB,VAV1,MEF2C,CHUK,GNA1
3,ELK1,MAP2K1	  
Altered	  T	  Cell	  
and	  B	  Cell	  
Signaling	  in	  
Rheumatoid	  
Arthritis	   3.24E-­‐02	  
TLR1,MAP3K14,TRAF3,IL1A,HLA-­‐DOA,CD79B,LTB,HLA-­‐
DMB,CD79A,FAS,HLA-­‐DQB1,CD40,CD80,HLA-­‐DOB,CHUK	  
Melanoma	  
Signaling	   3.55E-­‐02	   BRAF,RAC2,PIK3C2B,PIK3CA,MAPK1,CDK4,RAC1,PIK3CB,MAP2K1	  
Aryl	  
Hydrocarbon	  
Receptor	  
Signaling	   3.72E-­‐02	  
IL1A,MAPK1,BAX,NCOA3,FAS,AIP,CHEK1,EP300,MYC,PTGES3	  
(includes	  
EG:10728),CCND3,HSP90AB1,CDK4,HSP90AA1,NCOR2,NRIP1,RXRB
,NFE2L2,ALDH6A1,CDK2,ATM	  
14-­‐3-­‐3-­‐
mediated	  
Signaling	   3.72E-­‐02	  
TSC1,RAC2,PIK3C2B,PIK3CA,MAPK1,GRB2,TUBG1,RAC1,MAPK9,PL
CL2,BAX,MAP3K5	  (includes	  EG:4217),YWHAQ	  (includes	  
EG:10971),FOXO1,PIK3CB,GSK3B,ELK1,MAP2K1	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Fatty	  Acid	  
Elongation	  in	  
Mitochondria	   3.89E-­‐02	   HADHB,ECHS1,PPT1,HADHA,HADH	  
Glioma	  
Signaling	   3.89E-­‐02	  
RAC2,PIK3C2B,PIK3CA,RBL2,PA2G4,MAPK1,GRB2,SOS2,ABL1,RAC1
,E2F3,CDK4,SOS1,E2F5,PIK3CB,MAP2K1	  
Acute	  Phase	  
Response	  
Signaling	  
3.89E-­‐02	  
RAC2,IL1A,PIK3CA,FTL,MAPK1,NOLC1,SOS2,MAP3K5	  (includes	  
EG:4217),MAPK13,IKBKB,IKBKG,MAP3K7,SOS1,CHUK,MAP2K1,MA
P3K14,GRB2,MAP3K1,RAC1,MAPK9,TCF3,RIPK1,PTPN11,PIK3CB,EL
K1	  
Antigen	  
Presentation	  
Pathway	   3.89E-­‐02	  
HLA-­‐DOA,PSMB5,HLA-­‐DOB,CANX,HLA-­‐DMB,CD74,HLA-­‐DPB1,HLA-­‐
DPA1	  
Thrombopoieti
n	  Signaling	   4.37E-­‐02	  
MYC,PIK3C2B,PIK3CA,PTPN11,MAPK1,GRB2,SOS1,PIK3CB,STAT1,
MAP2K1	  
Glyoxylate	  and	  
Dicarboxylate	  
Metabolism	   4.68E-­‐02	   CS,MTHFD2,MDH1,MDH2,MTHFD1,ACO1	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